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Abstract 
Feline chronic gingivostomatitis (FCGS) is a severe inflammatory disease of the 
oral cavity that causes extreme pain and distress in affected cats.  Treatment 
options for FCGS are limited, and often unsatisfactory, and there is a poor 
understanding regarding its aetiology.  Recent literature indicates that several 
putative bacterial pathogens, including T. forsythia and P. circumdentaria, could 
be involved in the development and progression of disease by stimulating an 
excessive host immune response.  Understanding how the host responds to 
bacteria associated with FCGS is of importance to help identify novel targets for 
therapeutic strategies which are highly sought after.  The aim of this study was to 
investigate the impact of putative pathogenic bacteria on the host inflammatory 
response and test the anti-microbial potential of several compounds on an FCGS-
associated multispecies biofilm.   
 
A panel of bacteria found to be prevalent in FCGS were selected as a basis for in 
vitro research into the immune response from host cells following exposure to 
these bacteria.  The QUANTI-BlueTM assay was used to measure toll-like receptor 
(TLR) activation in human THP1-XBlueTM pro-monocytes.  IL-8 gene expression and 
protein release was measured from both human and feline cell lines by qPCR and 
ELISA, respectively.  Moreover, the antimicrobial potential of novel agents 
including carbohydrate-derived fulvic acid (CHD-FA), xylitol, berberine, and 
ubiquinol were assessed against a multi-species biofilm consisting of bacteria 
prevalent in FCGS.  The effect of these compounds on biofilm cell viability was 
determined using alamarBlue® and the impact on biofilm biomass was measured 
using the crystal violet assay. 
 
The results from this study have generally shown that putative pathogens such as 
T. forsythia, P. multocida subsp. multocida, and P. multocida subsp. septica at a 
multiplicity of infection (MOI) of 200 produced the greatest increase in secreted 
embryonic alkaline phosphatase (SEAP) expression/TLR activation (p<0.001) in 
human cells and significant IL-8 release in human and feline cells.  Commensal B. 
zoohelcum displayed an unexpected increase in IL-8 gene expression (p<0.01) and 
protein release (p<0.001) at an MOI of 200 in the squamous carcinoma cell feline 
cell line (SCCF1).  Furthermore, the novel agent CHD-FA showed to significantly 
decrease biofilm cell viability (p<0.01) and biomass (p<0.05) at 0.8% compared to 
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the untreated control, while berberine disrupted only biofilm biomass at 100 
µg/mL (p<0.05). Xylitol and ubiquinol had no significant impact on biofilm 
metabolic activity or biomass. 
 
To conclude, this research has highlighted the inflammatory potential of bacteria 
associated to FCGS and how this may reflect the chronic inflammation presented 
by the host during disease.  The development of a multi-species biofilm provided 
a platform to test novel compounds, highlighting its potential to be used as a tool 
in discovering appropriate therapeutic targets for FCGS and other biofilm 
infections. Such findings are valuable to enhance our understanding of the 
complex aetiology of FCGS and may help identify novel treatment interventions.  
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1 Introduction 
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1.1 General introduction 
 
Feline chronic gingivostomatitis (FCGS) is a feline oral disease which is 
characterised by severe, widespread inflammation within the oral cavity.  Cats 
affected with FCGS are often severely compromised, with inflammation typically 
lasting months to years, and may lead to the euthanisation of diseased cats in 
refractory cases.  Various bacterial species involved in human periodontal disease 
have been associated with FCGS and it has been implicated that viruses may play 
an important role in disease pathogenesis (Lobprise and Dodd, 2018).  However, 
the exact aetiology of FCGS remains elusive and the cause of chronic inflammation 
is considered to be multi-factorial involving interactions between oral bacteria, 
oral viruses, and the local immune system (Lyon, 2005; Lommer, 2013).  Due to 
the complex aetiology of FCGS, there are currently no satisfactory treatment 
options available that show consistent positive outcomes. The idiopathic nature 
of FCGS contributes to the complexity of the disease and makes the 
aetiopathogenesis an important area of research to progress in the development 
of preventative measures and novel effective methods of treatment. 
 
1.2 Feline Chronic Gingivostomatitis  
 
1.2.1 Nomenclature 
 
While feline chronic gingivostomatitis is the name commonly referred to in recent 
literature due to frequent occurrence in feline patients, various names have been 
used previously to refer to FCGS.  These include lymphocytic plasmacytic gingivitis 
stomatitis, chronic ulcerative paradental stomatitis, and chronic mucositis (Baird, 
2005; Lyon, 2005; Gengler, 2013).  In these cases, the syndrome was named based 
either on the location of lesions within the oral cavity or on the inflammatory 
infiltrates present during disease (Diehl and Rosychuk, 1993; Healey et al., 2007).  
 
 
 
 
 
 3 
1.2.2 Clinical presentation 
 
FCGS is marked by chronic, ulcerative inflammation within the oral cavity of cats.  
Unlike gingivitis, which does not extend beyond the mucogingival junction, 
stomatitis is a unique syndrome that can cause proliferative and ulcerative 
inflammation of the whole oral cavity (White et al., 1992).  It can affect all oral 
and pharyngeal soft tissues including the gingiva as well as the oral and pharyngeal 
mucosa.  The inflammation is typically confined to specific tissues and locations 
within the mouth, and the disease name is often defined by the distribution of 
inflammation apparent during disease, as shown in Figure 1.1.  In the most severe 
cases of FCGS, two main sites in the oral cavity are most commonly affected by 
painful ulcerous lesions.  These include tissue lateral to the palatoglossal folds 
known as the fauces (caudal mucositis), and mucosa overlying the 
premolar/molars extending to the buccal mucosa (alveolar mucositis). In some 
cases, swelling of the lips and loss of papillae on the tongue is also apparent 
(Southerden, 2010; Hennet et al., 2011). The salient clinical signs of 
gingivostomatitis include extreme oral pain and discomfort in affected animals.  
Other common clinical symptoms include halitosis, ptyalism (excessive salivation) 
and dysphagia often followed by weight loss due to difficulty eating (Bellei et al., 
2008).  Some cats may also display a decrease in grooming behaviour. The high 
severity of symptoms associated with FCGS can additionally lead to changes in 
affected cats’ demeanour including an increase in aggressiveness when handled 
as well as withdrawn behaviour (Lommer, 2013).  
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Figure 1.1: Terminology and localisation of inflammation in FCGS (Perry & 
Tutt, 2015). 
 
1.2.3 Prevalence 
 
Oral disease in cats is very common, with periodontal disease (affecting around 
85% of cats) and feline tooth resorption lesions (affecting 25-75% of cats) seen 
most frequently in practice (Bonello, 2007).  However, there is limited research 
investigating the prevalence of FCGS and so the commonness of the condition is 
uncertain.  In one study investigating a total of 753 cats, 12% of cats were found 
to be affected with FCGS (Verhaert and Van Wetter, 2004).  However, another 
larger study from the north-west of England showed an FCGS prevalence of 0.7% 
in a population of 4858 cats visiting veterinary practices (Healey et al., 2007).  
With approximately 10 million cats owned as pets in the United Kingdom (Murray 
et al., 2009), the estimated disease burden of FCGS translates to at least 70,000 
cases (0.7%) and upwards of 1 million cases (12%) in the UK alone.   
 
There are three distinct periods in a cat’s life when significant oral inflammation 
and stomatitis may be present.  The first is at 3-6 weeks during the time of kitten 
vaccinations.  At this period, inflammation may be elicited in response to vaccinal 
elements or due to increased dental plaque that coincides with deciduous tooth 
eruption.  The second period is marked by the eruption of permanent teeth at 4-
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6 months old, where more severe oral inflammation can be present and enhanced 
oral hygiene may be required as a method of control.  The largest group of cats 
found to be most commonly affected with oral inflammation and FCGS is at a mean 
age of seven years.  Adult cases of FCGS present clinical signs of inflammation 
with varying severity and location, with some cats believed to be more susceptible 
to the aetiological stimuli (Johnston, 2012).  The disease is seen in all breeds of 
domestic cats, however it has been suggested that pure-bred cats, including Maine 
Coon, are predisposed to the juvenile form of FCGS and can develop more severe 
lesions during disease (Wexler-Mitchell, 2018). 
 
1.3 Aetiopathogenesis 
 
The aetiopathogenesis of FCGS is not well understood, but it is believed that the 
chronic inflammation that is characteristic of FCGS is a result of an excessive 
immune response to oral antigenic stimulation.  The disease is thought to be 
multifactorial, with various possible causes (Lyon, 2005).  Oral antigens that are 
considered to be key factors in prompting the atypical immune response in FCGS 
include dental plaque accumulation, oral bacteria, and viral infections.  It is also 
believed that the chronic nature of the syndrome could be partially due to an 
underlying immune abnormality of the host (Southerden, 2010).  The 
multifactorial nature of FCGS is briefly summarised in Figure 1.2. 
 
1.3.1 Periodontal disease and tooth resorption  
 
Periodontal disease is often identified in cats with FCGS, due to inflammation 
spreading to the underlying bone and causing destruction of structures supporting 
the teeth (Hennet, 1997).  As gingivitis increases in severity, the gingival tissue 
shows a loss of integrity and ulceration of the gingival sulcus occurs, which allows 
bacteria and their by-products to migrate to deeper gingival structures and this 
can have an exacerbating effect on FCGS.  Moreover, type one tooth resorption, 
characterised by a normal periodontal ligament space and radiodensity of root 
structure, is also commonly present in cats with FCGS and is found in areas where 
periodontal inflammation is severe (Lobprise and Dodd, 2018).  Tooth resorption 
poses a significant complication in many FCGS cases, increasing the difficulty of 
tooth extraction due to ankylosis and/or weakening of roots.  A study investigating 
 6 
101 cats with FCGS found that all cats with FCGS had periodontitis and 49% of 
FCGS cases displayed external inflammatory tooth resorption (Farcas et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Algorithm of FCGS aetiology  
FCV: Feline calicivirus, FIV: Feline immunodeficiency virus, FeLV: Feline leukaemia 
virus, FCGS: Feline chronic gingivostomatitis. Adapted from (Bonello, 2007). 
 
 
1.3.2 Bacteriology 
 
1.3.2.1 Dental plaque  
 
Although research has indicated that FCGS is multifactorial in nature, it is 
generally accepted that plaque bacteria are a key contributing factor to the 
development of FCGS, with oral tissues overreacting to the presence of dental 
plaque.  Bacteria are ubiquitous in the feline oral cavity, with a vast number of 
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Altered epithelial integrity 
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stimulation 
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bacterial species present in both healthy and diseased states in the form of a 
complex protective plaque biofilm (Perry and Tutt, 2015; Harris et al., 2015).  
Biofilms provide advantages to bacteria over planktonic states, including 
protection from environmental stresses by the production of an extracellular 
polymer matrix and increased resistance to antimicrobials (Sedlacek and Walker, 
2007).  The biofilm adheres to the tooth surface and accumulates readily in all 
species.  It is rich in bacterial species, both commensal and pathogenic, as well 
as various glycoproteins and polysaccharides (Marsh & Bradshaw, 1995).  In the 
feline oral cavity, initial plaque development occurs within hours of the eruption 
of teeth or following cleaning.  An exposed tooth surface is covered by a layer of 
glycoprotein salivary pellicles, which act as a prime adhesive for bacteria as they 
provide a rich nutrient source (Zambori et al., 2012).  The first bacteria (early 
colonisers) to attach are mostly Gram-positive aerobic organisms that possess 
adhesion structures such as fimbriae which allow them to colonise and grow on 
the surface of the tooth.  Following growth of early colonisers, microcolonies 
begin to form which attracts more bacteria and triggers the development of the 
extracellular protein matrix (EPS).  The EPS acts as a protective barrier against 
antimicrobial agents and environmental stresses.  As dental plaque matures, the 
oxygen tension reduces and thus, the biofilm becomes more compliant to 
increased numbers of Gram-negative anaerobic species including bacilli and 
spirochaetes (Cate, 2006).  
 
Plaque bacteria can reside harmlessly within the oral cavity if plaque is 
consistently removed through an upkeep of oral hygiene, however, failure to 
remove plaque allows for the accumulation of a thick layer of microbes and a 
subsequent enrichment of inflammatory by-products associated with active 
gingival inflammation.  Consequently, plaque accumulation can lead to a variety 
of dental diseases in the host.  Within feline hosts, where daily brushing is not a 
common practice, a build-up of plaque will proceed to calcify to form the brown 
malodorous material known as dental calculus.  A positive correlation between 
feline age and calculus formation has been observed, as well as an increased 
frequency of calculus shown in cats fed wet, rather than dry, food (Gawor et al., 
2006).  Calculus has a rough surface and can promote further colonisation of 
bacteria (Perry and Tutt, 2015).  Without intervention, plaque and calculus build-
up can lead to the development of periodontal disease, which can progress from 
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gingivitis to irreversible periodontitis (Wolf and Hassell, 2006).  While cats 
affected by FCGS will often have very little calculus in the early stages of disease, 
by the time of clinical presentation, cats are also often suffering from significant 
periodontal disease (Hennet, 1997).  In cats with FCGS, plaque is considered as a 
major stimulant for the excessive oral inflammation, which is more severe than 
the typical progression of periodontal disease.  Understanding the involvement of 
plaque deposition in FCGS is of importance for the clinical management of this 
disease. 
 
1.3.2.2 The diseased feline oral microbiota  
 
Extensive research on the bacteria of the human oral cavity has revealed that it 
harbours a widely diverse bacterial community which grow within complex 
biofilms.  In human periodontal disease, as biofilms progress from supragingival to 
subgingival sites, there is a shift in the oral microbial community from 
predominantly commensal aerobes such as Actinomyces and Streptococcus species 
towards anaerobic, potentially pathogenic bacteria including Porphyromonas 
gingivalis and Tannerella species (Bascones and Figuero, 2005).  This follows the 
ecological plaque hypothesis, by which the subgingival environment selects the 
oral bacterial composition, with a shift to pathogenic bacteria driving the 
transformation from health to disease (Bartold and Van Dyke, 2013).  While the 
feline oral microbiome is less well studied, a shift in oral bacterial populations 
during the progression of periodontal disease has been implicated.  Early research 
found black-pigmented Bacteroides and Peptostreptococcus anaerobius to be of 
higher prevalence in cats with increasingly severe periodontal disease (Mallonee 
et al., 1988).  It has also been shown, through the use of next-generation 
sequencing, that there is a change in the proportion of phyla in feline subgingival 
plaque dependent on health state.  Cats with periodontal disease were found to 
have double the number of Firmicutes than healthy cats, while Bacteroidetes and 
Proteobacteria decreased in comparison (Harris et al., 2015).          
 
There is strong evidence that bacterial composition may also influence the 
development of FCGS in felines, with specific species of bacteria shown to be 
more prevalent in diseased states, as is often seen in periodontal disease. One 
study suggested that cats affected with FCGS have a reduced diversity of oral 
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bacteria in comparison to healthy cats (Dolieslager et al., 2011).    Early research 
indicated that FCGS could be caused by, or associated with, Bartonella henselae.  
It was discovered that cats co-infected with feline immunodeficiency virus (FIV) 
and B. henselae showed a higher prevalence of gingivitis, suggesting a possible 
connection in cats with clinical oral disease (Ueno et., al 1996).  However, there 
has since been no credible link found between Bartonella and FCGS.  It has since 
been discovered that felines with FCGS have an increased prevalence of 
Pasteurella multocida sub-species compared to healthy cats (Dolieslager et al., 
2011).  FCGS samples with a large overgrowth of P. multocida subsp. multocida 
have displayed a concurrent reduction of some bacteria found in high levels in 
healthy cats, such as C. canimorsus, possibly due to increased competition for 
nutrients.  Furthermore, bacteria such as Pseudomonas species, Tannerella 
forsythia and Porphyromonas circumdentaria have been commonly detected in 
cats with FCGS, and may be significant periodontopathogens (Dolieslager et al., 
2011).  Diseased felines that harbour T. forsythia are thought to present FCGS 
with the highest clinical disease severity.  Moreover, cats suffering from FCGS 
have shown to have statistically significantly increased levels of serum antibodies 
towards certain Gram-negative anaerobes such as Bacteriodes species (Sims et al., 
1990).  The increased prevalence of specific bacteria in FCGS cases suggests that 
they may be of aetiological significance in the development of disease. 
 
1.3.2.3 Bacterial sialidases 
 
Sialidases are a group of enzymes involved in the cleavage of terminal sialic acids 
from complex carbohydrates found on glycoproteins or glycolipids (Juge et al., 
2016).  Previous research has shown that the sialidase enzymes of some pathogenic 
bacteria, including Vibrio cholerae and Streptococcus pneumoniae, contribute to 
bacterial virulence within the host (Corfield, 1992).  These enzymes are also 
thought to particularly increase the virulence of bacteria that are present on 
and/or invade mucosal surfaces, likely due to a greater abundance of sialic acid 
in these tissues.  Sialidases have shown to act in tissue destruction, modulation of 
host innate immunity, as well as promoting biofilm formation (Soong et al., 2006).  
Research has found that organisms which have shown to be prevalent in the oral 
cavity during FCGS, including P. multocida species and T. forsythia, display 
medium-high sialidase activity (Scharmann et al., 1970).  T. forsythia has also 
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been prevented from attaching to epithelial cells when its sialidase activity was 
inhibited (Honma et al., 2011).  Investigating the sialidase activity of bacteria 
associated with FCGS could be valuable when developing targeted inhibitors to 
reduce bacterial attachment and invasion during disease.   
 
1.3.3 Viral influence  
 
Several viral agents have been linked to the occurrence of oral inflammation and 
FCGS in cats, including feline calicivirus, feline leukaemia virus, and feline 
immunodeficiency virus.  This is primarily due to an increased prevalence of FCGS 
observed in cats with various viral diseases (Tenorio et al., 1991; Quimby et al., 
2008; Belgard et al., 2010).  However, the pathological significance of viruses in 
FCGS is unclear.  It is thought that some viruses may not be a direct causative 
agent of disease, but instead exacerbate the symptoms of FCGS.  One proposed 
mechanism of viral involvement in FCGS suggests that immune dysregulation 
associated with viral infection could lead to oral microbial dysbiosis and a 
subsequent increase in pathogen colonisation and infection (Taniwaki et al., 
2013). 
 
1.3.3.1 Feline calicivirus  
 
Feline calicivirus (FCV) is a highly contagious ribonucleic acid (RNA) virus that is a 
major cause of respiratory infection in cats.  Privately owned pet cats kept in 
small numbers generally have lower rates of infection (around 10%) by FCV, with 
a greater prevalence of up to 40% found in shelter cats or catteries (Radford et 
al., 2007). FCV replicates in the oral and respiratory tissues, and has been 
identified as a cause of ulceration in the oral cavity of infected cats.  Several 
studies investigating felines chronically affected by FCGS have reported above 70% 
of these patients to also test positively for FCV following oropharyngeal swabbing 
(Knowles et al., 1989; Thompson et al., 1984; Harbour et al., 1991).  In the study 
by Thompson et al. (1984), FCV was isolated from 80% of cats with FCGS, compared 
to 0% of the control group.  However, more recent immunohistochemistry and PCR 
analysis of 26 FCGS-affected feline samples showed no detection of FCV in 
diseased cats (Rolim et al., 2017).  Moreover, another study of specific pathogen-
free cats infected with FCV were found to have associated acute oral 
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inflammation, but no cases developed into FCGS over a 10-month period (Knowles 
et al., 1991). While several studies have demonstrated a higher prevalence of FCV 
in cats with FCGS, a direct causal relationship between FCV and FCGS has not been 
established.  Further research is required to determine the involvement of FCV in 
FCGS, as a possible cause or modifying agent in disease. 
 
1.3.3.2 Feline leukaemia virus  
 
Feline leukaemia virus (FeLV) is an RNA retrovirus that infects up to 3% of cats in 
the United States and up to 5% of healthy cats in European countries (Gleich et 
al., 2009).  Infection with  FeLV can have several outcomes including development 
into a persistent viraemia, development of an inactive latent form, or the immune 
system may eliminate the virus (Rezanka et al., 1992).  A possible relationship 
between FeLV and FCGS has been suggested, since around 15% of cats infected 
with FeLV will show clinical signs of oral inflammation (Levy, 2005).  Studies 
investigating a link between FeLV and FCGS have shown inconsistent results.  In 
one study, 16.6% out of 36 cats with stomatitis tested positive for FeLV (White 
et., al 1992).  However, a study of 23 cats with FCGS found that all cats were 
negative for FeLV (Hennet, 1997).  Similarly, a study by Quimby et al. (2008) 
concluded that FeLV was not present in any of the cats with FCGS that were 
assessed.  Therefore, the involvement of FeLV in FCGS is questionable. 
 
1.3.3.3 Feline immunodeficiency virus  
 
Feline immunodeficiency virus (FIV) is an RNA lentivirus that affects up to 4.4% of 
cats worldwide (Richards, 2005).  FIV has been identified in cats with chronic oral 
lesions.  The severity of oral lesions has also shown to increase in cats with co-
infections of FIV with other viruses such as FCV (Dawson et al., 1991).  Studies 
investigating the association of FIV and FCGS have found conflicting outcomes.  A 
study that observed cats in the UK affected with FCGS found that 75% of cats were 
also positive for FIV compared to only 16% of the control group (Knowles et al., 
1989). However, a more recent study was unable to identify a significant 
difference in antibodies for FIV in serum samples between cats with FCGS and 
healthy controls (Belgard et al., 2010).  Some single case reports have also shown 
that felines affected with FCGS tested negative for FIV (Baird, 2005; Southerden 
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and Gorrel, 2007).  It is possible that the presence of both FeLV and FIV in cats 
with FCGS is coincidental, as the prevalence of these viruses in affected cats has 
shown to not differ significantly from the general feline population (Dolieslager 
et al., 2011).  Further research is required to fully understand the viral role in 
FCGS aetiology.   
 
1.3.4 Immunology of FCGS  
 
1.3.4.1 Mucosal cells  
 
Various immune cells are present within the oral cavity including lymphocytes, 
dendritic cells, macrophages, and mast cells (Arzi et al., 2010).  Inflammatory cell 
infiltrates are usually abundant in FCGS, with research suggesting that oral lesions 
present in affected cats represent a complex and destructive inflammatory 
process that frequently extends from the epithelium to submucosal tissues (Harley 
et al., 2011).  While the inflammatory infiltrate present in the feline oral cavity 
during FCGS is not entirely understood, plasma cells and lymphocytes are believed 
to be predominant within FCGS oral lesions (Johnessee and Hurvitz, 1983).  
Histological imaging of moderate to severe FCGS has displayed an expansion of 
the mucosal lamina propria by sheets of mature plasma cells, including the 
presence of Mott cells (Murphy et al., 2019).  Mott cells are atypical plasma cells 
which contain immunoglobulins within their cytoplasm (Bain, 2009).  Moreover, 
increased numbers of CD3+ T lymphocytes, L1+ cells, and elevated levels of MHC 
class II expression have been associated with greater severity of inflammation in 
FCGS oral lesions (Harley et al., 2011).  Small increases in the proportion of mast 
cells, dendritic cells and macrophages have also been noted (Harley et al., 2003a; 
Vapniarsky et al., 2020).   There has also shown to be a shift in salivary 
immunoglobulins in cats with FCGS, from primarily IgA in healthy cats to primarily 
IgG and IgM in affected cats (Harley et al., 2003b).  A decrease in IgA levels in 
saliva can weaken the mucosal defence against pathogens and therefore could 
contribute to the development of FCGS.   
 
Furthermore, CD8+ T cells have been found in greater abundance than CD4+ T 
cells in mucosal samples of FCGS-affected cats (Harley et al., 2011).  In general, 
CD4+ T cells primarily act by regulating other immune cells through the release of 
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cytokines or by direct cell contact.  CD8+ T cells, however, are cytotoxic and 
typically kill target cells that have been virally infected or have undergone 
neoplastic transformation.  When CD8+ cells encounter the target antigen, they 
differentiate into an effector phenotype which is marked by increased levels of 
pro-inflammatory cytokines and killing of target cells.  Some of these cells also 
acquire a memory phenotype, which allows the cell to persist long-term in the 
absence of an antigen (Kalia and Sarkar, 2018).  Memory cells with “effector 
memory” can attach and reside in sites of inflammation, such as within the oral 
mucosa (Sallusto et al., 2004).  Elevated levels of CD8+ T cells in FCGS could 
therefore suggest an elicited cytotoxic cell-mediated immune response, 
supporting the possible involvement of viral agents in disease (Harley et al., 2011).  
In addition, one study has demonstrated that there is a notable increase in 
effector memory CD8+ lymphocytes and a corresponding decrease in central 
memory CD8+ lymphocytes in felines with FCGS in comparison to a healthy control 
group (Vapniarsky et al., 2020).  This suggests that the persistent inflammation in 
FCGS could be due to CD8+ cells remaining in an activated state.  The complex 
immune response found in FCGS most likely drives the chronic inflammation that 
presents during disease.  
 
1.3.4.2 Toll-like receptors  
 
Toll-like receptors (TLRs) are a class of proteins present on the surface of host 
leukocytes which can sense and respond to invading pathogens by initiating the 
production of cytokines and activating the innate and adaptive immune response 
(Janeway and Medzhitov, 2002). Signature molecules on the surface of 
microorganisms known as pathogen-associated molecular patterns (PAMPs) are 
recognised by the host with specific recognition receptors, including TLRs, which 
allows the host to determine the nature of a pathogen and induce an appropriate 
inflammatory response.  Notable changes in host TLR expression can give insight 
into the possible pathogens involved in the aetiopathogenesis of a disease (Akira 
and Takeda, 2004).  Using quantitative PCR, Dolieslager et al. (2013) 
demonstrated significantly elevated mRNA levels of TLR2 and TLR7 in mucosal 
tissue biopsies of cats affected with FCGS compared to a healthy control group.  
Additionally, increased levels of TLR mRNAs were displayed when putative 
pathogens T. forsythia (TLR2, TLR4, TLR7 and TLR9), P. circumdentaria (TLR2 and 
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TLR3) and FCV (TLR2) were present in affected cats.  TLR2 and TLR9 both 
recognise many bacterial, fungal and viral substances, and mRNA expression of 
TLR2 has shown to increase when it is activated (Weiss et al., 2004).  TLR4 
activation can occur after binding of several Gram-negative bacteria and envelope 
proteins of viruses, while TLR7 responds to single-stranded RNA and anti-viral 
compounds (Akira and Takeda, 2004).  The increased expression of these TLRs and 
heightened activity of the immune system is most likely the cause for the clinical 
manifestation of FCGS, possibly in response to the altered oral microbiota or viral 
presence that has been implicated in FCGS.  Further research is required to 
evaluate the influence of FCGS-associated putative pathogens individually, and in 
combination, on TLRs and the immune response. 
 
1.3.4.3 Cytokines and chemokines  
 
Following TLR activation, there is an increase in the transcription of many genes 
including those for cytokines, which act as signalling molecules to mediate and 
regulate the inflammatory response.  Studies have reported increased mRNA 
expression of a range of pro-inflammatory cytokines in felines with FCGS, 
including IL-2, IL-4, IL-6, IL-10, IL-12, IFN-γ, TNF-α and IL-1β (Harley et al., 1999; 
Dolieslager et al., 2013).  Pro-inflammatory cytokines are involved in both innate 
and adaptive pathways, promoting the progression of the inflammatory response 
which may explain the severe inflammation characteristic to FCGS.  Furthermore, 
there is a shift from predominantly T-helper lymphocyte type 1 (Th1) cells in 
healthy cats to a mixed environment of Th1 and Th2 cells in cats with FCGS (Harley 
et al., 1999).  Th1 cells produce cytokines such as IFN- γ and IL-2 and play a role 
in the activation of macrophages and delayed hypersensitivity responses.  Th2 
cells produce several cytokines including IL-4, IL-6, IL-9, IL-10 and IL-13, and are 
involved in the stimulation of B cells (Cruse and Lewis, 2010).  The chronic 
inflammation found in FCGS is likely a result of the amplified immune response in 
cats with FCGS. 
 
Interleukin-8 (IL-8) is a pro-inflammatory chemokine that is a major chemotactic 
factor in acute inflammation, involved in the recruitment of neutrophils to sites 
of inflammation and tissue infiltration (Haas et al., 2016).  IL-8 has been used in 
both in vitro and in vivo studies to measure inflammation in human periodontal 
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disease (Fukui et al., 2013; Dommisch et al., 2015).  In humans, an increase in 
levels of IL-8 has been shown in gingival tissues, correlating to the severity of 
periodontal disease (Noh et al., 2013).  While its specificity for oral disease in cats 
is not known, several studies have identified increased levels of IL-8 in other 
chronic felines inflammatory diseases (Habenicht et al., 2012; Gruen et al., 2017).  
Therefore, IL-8 may be useful as a marker in cats with an abnormal inflammatory 
response such as in FCGS. 
 
1.4 Diagnosis  
 
FCGS is a poorly defined condition where inflammation extends beyond the 
mucogingival line.  As FCGS is likely to have multifactorial aetiology, there is no 
definitive diagnostic test as underlying causes may differ between cases.  A 
veterinary surgeon will thoroughly examine a cat’s oral cavity under anaesthesia 
before reaching an accurate diagnosis.  This allows for other potential causes of 
inflammation in the mouth such as azotaemia, squamous cell carcinoma, and 
periodontal disease to be ruled out to avoid misdiagnosis.  Furthermore, a full 
dental radiograph is strongly recommended to evaluate root remnants, as most 
cats with FCGS will also suffer from a form of periodontitis which will require 
treatment (Farcas et al., 2014).  If there is still doubt over the diagnosis, biopsies 
should be taken which allows for the elimination of neoplasms (Milella, 2008).  
Biopsies can also be used to evaluate the symmetry of oral lesions which further 
helps to correctly diagnose the disease.  Inflammatory lesions in FCGS are usually 
bilaterally symmetrical (Niemiec, 2008). PCR technology can be used to identify 
carriage of oral viruses.  
 
1.5 Disease prevention 
 
Establishing preventative measures for FCGS has proven difficult due to the elusive 
aetiology of the disease.  However, a sensible method of maintaining the oral 
health of a cat as much as possible would be to upkeep good oral hygiene.  This 
would focus on the removal of dental plaque and disruption of bacterial biofilms 
in the mouths of affected cats and in turn, reduce the risk of periodontal disease 
that can often develop in cats with FCGS.  A variety of products are available to 
maintain dental hygiene in cats including toothpaste and mouthwash.  A reduction 
 16 
in dental calculus has been shown in cats that have their teeth brushed once or 
twice weekly (Richardson, 1965).  A specific diet can also be implemented to 
improve dental care.  The diets often include large kibbles that are designed to 
clean the teeth during eating by mechanically reducing plaque build-up from the 
surface of teeth.  Dried food is generally believed to benefit oral health in 
comparison to moist food (Studer and Stapley, 1973).  One recent study found that 
the probability of cats developing poor oral health is lower when fed a dry diet 
(Mata, 2015).  It has also been suggested that the oral health of cats may improve 
when artificial ingredients are removed from food (Addie et al., 2003).   
 
1.6 Treatment options  
 
The treatment of FCGS is challenging as the response to treatment is 
unpredictable.  In general, the treatment of FCGS can be approached with surgical 
and/or medical intervention.  Improvement is often observed in around two-thirds 
of cases, while some cats will not recover (Jennings et al., 2015).  Many cats will 
continue to show persistent or relapsing lesions and will require chronic 
management of disease.  As the aetiology of FCGS is unknown, effective targeted 
treatment options remain limited.  Therefore, most current treatments aim to 
reduce inflammation as well as minimise pain and discomfort that accompanies 
FCGS.  
 
1.6.1 Dental extraction 
 
Surgical management of FCGS typically involves the extraction of all premolars 
and molars with the hypothesis that this can remove stagnant plaque bacteria and 
decrease clinical symptoms (Bellei et al., 2008). This is currently the 
recommended method of treatment for FCGS as it has shown to provide the best 
long-term outcome.  Studies have shown varying success rates of dental extraction 
in cats with FCGS, with 50-60% of cases requiring no further treatment, 20-40% of 
cases show signs of improvement and the remaining 10-20% of cases will not 
improve following the intervention (Hennet, 1997; Girard and Hennet, 2005; Bellei 
et al., 2008).  In particularly severe cases, if there is no positive response to 
partial-mouth extraction, cats may require a full dental extraction (including 
canines and incisors) as a second stage of treatment (Jennings et al., 2015). 
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Post-operative plaque control often involves the use of a topical chlorhexidine 
(CHX) treatment.  CHX paste or gel is believed to be one of the most important 
and effective treatment options available, both short- and long-term, to control 
FCGS and reduce the overall antigenic burden.  CHX is widely accepted as the 
‘gold standard’ in the management of human oral biofilm diseases, shown to have 
a broad-spectrum of activity against bacteria, fungi and viruses (Herrera, 2013; 
Lim and Kam, 2008).  One problem with this treatment is finding a suitable product 
for affected felines, as some gels have a bitter taste and may cause side effects 
in some animals (Lobprise and Dodd, 2018).  Identifying a potentially natural 
alternative compound that has the potency of CHX but with minimal adverse 
effects could be highly valuable in the search for therapeutic measures for FCGS. 
 
1.6.2 Antibiotic therapy  
 
Antibiotics are often advised as a first-line treatment in an attempt to alleviate 
excessive inflammation or allow oral tissue to heal following surgery.  The 
antibiotics prescribed should preferably target both aerobic and anaerobic 
pathogenic bacteria in the oral cavity. Recommended antibiotics include 
clindamycin, amoxicillin, metronidazole, and doxycycline (Frost and Williams, 
1986; Harvey, 1991; Lyon, 2005; Wiggs, 2007).  However, the use of antibiotics in 
FCGS is thought to worsen the long-term prognosis of some cases, as they may 
become ineffective and lead to super-infections (Bonello, 2007).  Moreover, 
Pasteurella multocida species, which have shown to be highly prevalent in cats 
with FCGS, appear to be clindamycin resistant and therefore this drug may not be 
effective in all cases (Dolieslager et al., 2011).  Antibiotic therapy is more 
favourable as a short-term intervention for FCGS to reduce oral discomfort. 
 
1.6.3 Anti-inflammatory and immunosuppressive drugs 
 
Corticosteroids are drugs that mimic the effects of hormones that are normally 
produced in the adrenal glands.  They have been used to treat FCGS due to having 
anti-inflammatory properties.  Prednisolone is a short-acting corticosteroid that 
is often used to control inflammation in FCGS.  In one study using several 
corticosteroids as a treatment method for FCGS, an improvement was observed in 
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up to 80% of cases (White et al., 1992).  However, while these drugs may improve 
clinical symptoms of disease, they can also lead to a more progressive form of 
FCGS that will not respond to treatment and therefore, they are often used only 
as a “rescue treatment”.  Additionally, the use of corticosteroids is generally 
contraindicated because of an associated increased risk of obesity and diabetes 
mellitus (Niemiec, 2008).  
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are another type of anti-
inflammatory used to reduce the effect of the inflammatory response in FCGS.  
NSAIDs work by blocking the COX enzymes and reduce prostaglandins throughout 
the body.  The best option of NSAID for FCGS appears to be meloxicam, which 
would often be prescribed in combination with an antibiotic (Hennet et al., 2011).  
However, there is limited research reporting the efficacy of NSAIDs for FCGS.  
 
1.6.4 Interferon treatment 
 
Interferons (IFNs) are a group of proteins used in cell communication throughout 
the immune system that can interfere with viral replication (Hennet et al., 2011).  
Recombinant feline interferon omega (rFeIFN-ω) is an immunomodulatory drug 
which has been described as effective for the treatment of feline viruses including 
FCV and feline herpesvirus-1 (Truyen et al., 2002).  One study investigated the 
use of rFeIFN-ω compared to prednisolone in FCGS-affected cats that were 
refractory to extraction therapy.  There was found to be no statistically significant 
difference in clinical signs when using rFeIFN-ω compared to prednisolone, 
however the use of rFeIFN-ω did show to significantly reduce the pain, and 
increase the activity, of affected cats throughout the study (Hennet et al., 2011).  
Furthermore, Leal et al. (2013) conducted a case study with 2 cats and showed 
that treatment of oral lesions with rFeIFN-ω resulted in a significant decrease in 
inflammation.  Research suggests that long-term prognosis with the use rFeIFN-ω 
exceeds the potential of other methods of treatment for this condition (Hennet 
et al., 2011).   
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1.6.5 Mesenchymal stem cell therapy 
 
The efficacy of mesenchymal stem cells (MSCs) administered intravenously to cats 
with refractory FCGS has been reported with promising results.  MSCs are 
multipotent stem cells that can modulate innate and adaptive immunity through 
inhibition of T-cell proliferation, downregulation of MHC II, and inhibition of 
dendritic cell maturation (Clark et al., 2017; Quimby and Borjesson, 2018).  
Autologous MSCs have shown to be nonimmunogenic and safe in both humans and 
animals, with few reports of adverse reactions following long-term use (Quimby 
et al., 2013; Kol et al., 2015).  One study showed a positive response rate of over 
70% when cats with refractory FCGS were treated with autologous adipose-derived 
MSCs, with over 40% showing complete resolution of disease (Arzi et al., 2016).  
Further investigations to determine the potential of MSCs as a treatment option 
for FCGS are ongoing, including clinical trials to gain a greater understand of the 
mechanism of action of MSCs in disease (Quimby and Borjesson, 2018).    
 
 
1.7 In vitro biofilm models 
 
Many studies have highlighted the diverse nature of dental plaque biofilms and 
that biofilm composition may influence a healthy or disease state in both human 
and feline oral disease.  Various plaque biofilm models have been developed in 
the study of human oral diseases to investigate biofilm formation and 
antimicrobial susceptibility, and to further understand the impact of specific 
bacteria on disease (Periasamy and Kolenbrander, 2009; Park et al., 2014; 
Guggenheim et al., 2001).  Biofilm models of human supra- and sub- gingival 
plaque have previously been developed using defined bacterial species or from 
undefined plaque samples.  While using an undefined bacterial model more closely 
reflects the species diversity present in the oral cavity, defined biofilm models 
have shown to be favourable in the study of biofilms due to their reproducibility.  
It also allows the study of specific bacterial biofilms of interest, where exact 
mechanisms of biofilm formation and species-specific interactions can be 
identified.    
 
While plaque biofilm models are extensively used in the study of human 
periodontal disease, there is no evidence of the development of a feline oral 
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plaque biofilm.  A five species human caries biofilm model with S. oralis, S. mitis, 
A. naeslundii, S. downei and S. sanguinis was created to study the biofilm 
formation when treated with bovine milk osteopontin, with an overall reduction 
in the biofilm biomass shown (Schlafer et al., 2012).  Furthermore, a complex 
eleven species oral biofilm has been developed to assess the viability of individual 
species following treatment with oral cleansing regimes (Sherry et al., 2016).  The 
use of in vitro biofilm models could be beneficial in the study of feline oral 
disease.   
 
1.8 Summary 
 
FCGS is a poorly defined disease, marked by localised chronic inflammation of soft 
oral tissues including the gingiva and oral mucosa.  The aetiology is believed to be 
a manifestation of an overreactive immune response to antigenic stimulation, with 
bacteria and viruses believed to be important contributing factors to the 
development and progression of disease.  While there are a several treatments 
available for FCGS, no method of intervention is completely satisfactory to cure 
the disease in all cases.  Until the complex multifactorial nature of FCGS can be 
understood, it will remain difficult to find an appropriate method of intervention.  
This makes the aetiopathogenesis of FCGS an important area of research to 
ultimately allow for the development of effective preventative measures and 
novel methods of treatment to tackle this debilitating disease. 
 
1.9 Aims of study 
 
1.   To exploit multiple cell lines to investigate, in vitro, the initial innate 
immune responses (via cytokine release and mRNA expression) to putative 
pathogenic bacteria associated with FCGS.  The cell models include THP1-
XBlueTM human pro-monocytes and SCCF1 feline oral squamous carcinoma 
cells. 
2.   To develop a multi-species biofilm with FCGS putative pathogens and 
commensal microorganisms and test with biologically active agents. 
 
 
 21 
2 Host cell inflammatory response following 
exposure to bacteria associated with FCGS 
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2.1 Introduction and Aims 
 
FCGS is a complex syndrome with a myriad of factors that may contribute to 
disease aetiology.  It is commonly believed that cats with FCGS suffer from an 
over-reactive immune response to low levels of oral antigens, including dental 
plaque.  Specific bacteria have been identified as highly prevalent in diseased cats 
showing abnormal levels of inflammation, with Tannerella species and 
Porphyromonas species implicated to be key pathogens involved in the progression 
of disease.  Moreover, Pasteurella multocida species have shown to be highly 
represented in FCGS, suggesting an association with disease pathogenesis 
(Dolieslager et al., 2013).   
 
The colonisation and accumulation of dental plaque bacteria in the feline oral 
cavity, like in periodontal disease, may stimulate a variety of host inflammatory 
responses.  Phagocytes are a first line of host defence and are involved in clearing 
pathogens by phagocytosis, degranulation, and through the recruitment of other 
immune cells to the site of infection (Paltrinieri, 2008).  Some phagocyte cells 
have toll-like receptors (TLRs) on their surface which allow for the initial 
detection of pathogens (Janeway and Medzhitov, 2002). TLRs activate 
downstream signalling pathways, such as the nuclear factor NF-κB pathway, that 
lead to the induction of innate immune responses by releasing pro-inflammatory 
chemokines and cytokines like interleukin-8 (IL-8) and tumour necrosis factor 
alpha (TNFα) (Kawasaki and Kawai, 2014).  The pro-inflammatory chemokine IL-8 
has been implicated in chronic inflammation (Harada et al., 1996).  These 
processes are not only involved in eliciting immediate host responses such as 
inflammation, but also orchestrate antigen-specific adaptive immune responses 
(Janeway and Medzhitov, 2002).   
 
The ability of the host to mount an appropriate inflammatory response is critical 
for maintaining oral health and host-microbial symbiosis.  Due to lack of oral 
hygiene in felines, plaque bacteria may accumulate at the gingival margin and 
lead to the over-reactive immune response and consequent chronic inflammation 
that is characteristic during FCGS.  Investigating the interactions between host 
cells and putative pathogens of FCGS is vital to provide a greater understanding 
of the abnormal inflammation observed in affected cats. 
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The aim of this chapter is to investigate how FCGS-associated bacteria may 
modulate innate immune inflammatory responses at a gene and protein level, 
which may contribute to the chronic inflammation observed in FCGS.  
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2.2 Materials and Methods 
 
2.2.1 Bacterial culture and standardisation  
 
A selection of laboratory strains of commensal, known pathogenic and potentially 
pathogenic bacteria associated with FCGS were used in this study.  These included 
Pasteurella multocida subsp. multocida DSM 16031 and Pasteurella multocida 
subsp. septica DSM 23071 which were grown on Colombia blood agar (CBA) [Oxoid, 
Basingstoke, UK] supplemented with 5% sheep blood and maintained for 24 h at 
37°C in 5% CO2.  Bergeyella zoohelcum DSM 16783 was grown on CBA 
supplemented with 5% horse blood and maintained for 48 h at 37°C in 5% CO2.  
Porphyromonas circumdentaria DSM 103022 and Porphyromonas gingivalis ATCC 
33277 were maintained at 37°C on fastidious anaerobic agar (FAA) [Lab M, 
Lancashire, UK] supplemented with 5% horse blood under anaerobic conditions 
(85% N2, 10% CO2 and 5% H2 [Don Whitley Scientific Limited, Shipley, UK]) for 4 
days.  Tannerella forsythia ATCC 43037 was maintained at 37°C on FAA 
supplemented with 5% horse blood containing 10 µg/mL N-acetylmuramic acid 
(NAM) for 4 days under anaerobic conditions.  All isolates were stored in 
Microbank® vials [Pro-Lab Diagnostics, Wirral, UK] at -80°C until required. 
 
A loopful of each isolate was inoculated into 10 mL of the appropriate growth 
medium for bacterial quantification.  P. multocida sub-species and B. zoohelcum 
were propagated in 10 mL brain heart infusion broth (BHI) [Sigma-Aldrich, 
Gillingham, UK] for 24 h at 37°C in 5% CO2.  T. forsythia was grown in 10 mL BHI 
containing 5% fetal bovine serum (FBS) [Sigma-Aldrich] and 0.001% NAM for 4 days 
under anaerobic conditions.  P. circumdentaria and P. gingivalis were grown in 10 
mL Schaedler’s anaerobic broth [Oxoid] for approximately 4 days under anaerobic 
conditions.  Cultures were washed twice by centrifugation at 3000 rpm for 10 
minutes and re-suspended in 10 mL phosphatase buffer saline (PBS) [Sigma-
Aldrich].  All cultures were standardised to a final stock concentration of 1 x 109 
cells/mL in PBS by measuring the optical density at 550 nm.  The bacterial 
suspensions were subjected to heat at 55°C for 30 minutes to kill the bacteria and 
then stored at -20°C for further studies. 
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2.2.2 THP1-XBlueTM human cell culture 
THP-1 cells are a human pro-monocytic cell line, derived from the peripheral 
blood of an acute monocytic leukaemia patient (Tsuchiya et al., 1980). The THP1-
XBlueTM cell line [InvivoGen, UK] is a derivative of THP-1, specifically engineered 
to monitor the NF-κB signal transduction pathway.  THP1-XBlueTM cells feature an 
NF-κB and AP-1-inducible secreted embryonic alkaline phosphatase (SEAP) 
reporter gene.  SEAP is secreted by THP1-XBlueTM cells in response to TLR 
stimulation and can be measured using QUANTI-BlueTM, a SEAP detection reagent 
that turns purple/blue in the presence of SEAP.    
THP1-XBlueTM cells were cultured in RPMI (Roswell Park Memorial Institute)-1640 
medium supplemented with 2 mM L-glutamine, 25 mM HEPES, 10% (v/v) heat-
inactivated fetal bovine serum (FBS) [Sigma-Aldrich], 100 U/mL penicillin, 100 
µg/mL streptomycin, 100 µg/mL ZeocinTM and 100 µg/mL NormocinTM.  Cells were 
seeded at 7 x 105 cells/mL in a 75 cm2 flask [Corning Life Sciences, NY] and 
maintained at 37°C in 5% CO2.  Cells were allowed to reach approximately 80% 
confluency before passage.  To passage cells, cells were washed twice in PBS by 
centrifugation for 5 minutes at 1000 rpm and then re-suspended in 5 mL of RPMI-
1640 [Sigma-Aldrich].  The cells (10 µL) were stained with 0.4% trypan blue 
solution (10 µL) and live cells were counted on a haemocytometer under a light 
microscope.  Cells were re-seeded at 1 x 106 cells/flask in RMPI-1640.  THP1-
XBlueTM cells were used as a comparative human control in this study.     
Frozen stocks of THP1-XBlueTM were prepared for long-term storage in liquid 
nitrogen.  Cell suspensions were standardised to 1 x 106 cells/mL in RPMI-1640 
supplemented with 20% fetal bovine serum (FBS).  Equal volumes of 20% dimethyl 
sulfoxide (DMSO) and THP1-XBlueTM cells were transferred to a cryovial to obtain 
a final volume of 1 mL.  The vials were stored overnight at -80°C to ensure the 
cells were cooled slowly before final storage in liquid nitrogen.  Cells were revived 
from frozen stocks by thawing at 37°C before transferring into a cell culture flask 
containing warm RPMI-1640.  For experiments, cells were seeded at 2 x 105 
cells/mL in RPMI-1640. 
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2.2.3 SCCF1 feline cell culture 
The squamous cell carcinoma feline (SCCF1) cell line was developed from a 
laryngeal squamous cell carcinoma of a cat (Tannehill-Gregg et al., 2001).  SCCF1 
cells were acquired from the original developers of the cell line at The Ohio State 
University (USA).  Briefly, SCCF1 cells were propagated in William’s E medium 
[Sigma-Aldrich] supplemented with 2 mM L-glutamine, 0.05 mg/mL gentamicin, 
10 ng/mL epidermal growth factor and 10% FBS.  Cells were maintained at 37°C 
in 5% CO2 until 90% confluence.  To passage cells, the medium was removed and 
cells were washed twice with Dulbecco’s phosphate-buffered saline 
[ThermoFisher, Epsom, Surrey, UK] followed by the addition of 3 mL of 0.25% 
trypsin-0.53 mM EDTA [ThermoFisher] to disaggregate the cells from the surface.  
Once detached, 10 mL of media was added to the cells to terminate trypsinisation.  
A cell count was performed by staining cells with 0.4% trypan blue and counting 
viable cells on a haemocytometer under a light microscope.  Cells were re-seeded 
at 1 x 106 cells/flask in supplemented William’s E medium. 
Frozen stocks of SCCF1 cells were prepared as described for THP1-XBlueTM 
previously (section 2.2.2). For experiments, SCCF1 cells were seeded at 2 x 105 
cells/mL in William’s E medium.    
2.2.4 Bacterial stimulation of cell lines 
Each cell line (THP1-XBlueTM and SCCF1) was stimulated with a panel of bacteria 
thought to be involved in the aetiology and chronic inflammatory response found 
in FCGS.  Cells were seeded in a 96-well plate at a concentration of 2 x 105 
cells/mL in RPMI-1640 and incubated overnight at 37°C in 5% CO2.  The bacterial 
stocks of 1 x 109 cells/mL were subject to a series of double serial dilutions using 
PBS to prepare a range of multiplicities of infection (MOI) of bacteria – 200, 100, 
50, 25 and 12.5 – with bacterial concentrations from 4 x 107 bacteria/mL (MOI 200) 
to 1.25 x 106 bacteria/mL (MOI 12.5).  Following incubation, 20 µL of each 
bacterial dilution was added to the cell suspension.  RPMI-1640 served as a 
negative control.  The plate was then incubated at 37°C in 5% CO2 for 24 h.  At 24 
h, the plate was centrifuged at 1000 rpm for 1 minute before extracting 100 µL of 
supernatant which was stored at -20°C.  The remaining cell/bacterial suspension 
was stored at -80°C.  Supernatants and cell lysates were retained to assess the 
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release of pro-inflammatory mediator and changes in mRNA expression following 
stimulation.  RNA was extracted as described in section 2.2.6 and ELISA techniques 
were performed as described in section 2.2.11.  
2.2.5 QUANTI-BlueTM assay 
 
Toll-like receptor (TLR) activation was measured using the THP1-XBlueTM cell line 
which produces SEAP in response to TLR activation, and induction of the NF-κB 
transcription factor.  To quantify the levels of SEAP from the exposed THP1-
XBlueTM cells, a QUANTI-BlueTM colorimetric enzyme assay [InvivoGen] was used to 
assess all supernatants harvested from the bacterial stimulation experiments.  
QUANTI-BlueTM turns purple/blue in the presence of SEAP.  Each sample was 
diluted 1:10 with warmed QUANTI-BlueTM and incubated at 37°C for 4 h.  Following 
the incubation period, the optical density (OD) was recorded at 630 nm using a 
plate reader.    
 
2.2.6 RNA extraction 
 
Following stimulation of cell lines with various FCGS-associated bacteria, cell 
supernatants were removed and RNA was extracted from host cells using the 
RNeasy Mini kit [Qiagen Ltd, Crawley, UK] in accordance with the manufacturer’s 
instructions.  Host cell samples were lysed with the addition of 350 µL buffer RLT.  
The resultant lysate was transferred to an RNase-free microfuge tube and mixed 
thoroughly with 350 µL of 70% ethanol.  Each 700 µL sample was then transferred 
to an RNeasy spin column placed within a 2 mL collection tube and centrifuged at 
13000 rpm for 15 seconds, with the flow-through discarded.  The RNA on the 
column membrane was washed with 350 µL of buffer RW1 by centrifugation at 
13000 rpm for 15 seconds and flow-through discarded.  A solution containing 10 
µL of DNase 1 stock solution and 70 µL of buffer RDD was added onto the RNeasy 
column membrane and incubated at room temperature for 15 minutes.  Next, 
buffer RW1 was again added to the column and centrifuged at 13000 rpm for 15 
seconds with flow-through discarded.  The RNA on the membrane was precipitated 
by the addition of 500 µL of buffer RPE and centrifugation at 13000 rpm for 15 
seconds, followed by an additional centrifugation at 13000 rpm for 1 minute to 
dry the membrane.  Finally, 30 µL of RNase-free water was added directly to the 
membrane before centrifugation at 13000 rpm for 1 minute to elute the RNA.  RNA 
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was collected and quantified using a spectrophotometer or stored at -80°C until 
required.   
 
2.2.7 RNA quantification 
 
The RNA extracted from host cells was quantified using the NanoDrop 1000 
spectrophotometer [Thermo Scientific, Wilmington, USA] to assess the quality and 
concentration of RNA obtained.  The NanoDrop pedestal was loaded with 1.5 µL 
of RNA from each sample.  To measure the purity of the RNA, the ratio of 
absorbance was measured at 260 and 280 nm, where RNA with a 260/280 ratio 
greater than 1.8 was deemed to be of high quality.  Samples were stored at -20°C 
until required for cDNA synthesis. 
 
2.2.8 cDNA synthesis 
 
Complementary DNA (cDNA) synthesis was achieved using the High-Capacity RNA-
to-cDNATM reverse transcription (RT) kit [Thermofisher].  Two hundred nanograms 
of RNA was added to 4 µL of RT master mix, with a final volume of 20 µL made up 
using RNase-free water.  Controls which did not contain the reverse transcriptase 
enzyme were also included.  Samples were centrifuged at 1000 rpm for 2 minutes 
to remove air bubbles.  Samples were then loaded on to the thermal cycler [Bio-
Rad, Watford, UK].  The cDNA was synthesised using the following thermal cycling 
conditions: 5 minutes at 25°C, 30 minutes at 42°C, 5 minutes at 85°C and a final 
hold stage at 4°C.  Samples were then stored at -20°C for use in PCR.     
 
2.2.9 Primer design 
 
Primers used for PCR were either found in previously published literature or 
designed based upon their sequence, which was obtained from the National Centre 
for Biotechnology Information (NCBI, Bethesda, USA).  To design primer sets in-
house, the web-based Primer-Blast software (NCBI) was used 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/).  Primers were designed to 
yield a PCR product size of 70-120 base pairs.  The National Institute of Health’s 
Basic Local Alignment Search Tool (NIH-BLAST) was used to check primer 
specificity (http://www.nlm.nih.gov/BLAST). Oligonucleotides matching the 
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resulting primer sequences were synthesised [Invitrogen, Paisley, UK] for the 
target genes of interest (Table 2.1). 
 
2.2.10 Real-time quantitative PCR  
 
Cytokine gene expression was analysed using SYBR® Green [Invitrogen, Paisley, 
UK] based real-time quantitative PCR (RT-qPCR), using glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as a housekeeping gene (Barber et al., 2005).  
The primers used are listed in Table 2.1.  Each well contained 12.5 µL of SYBR® 
green master mix [Invitrogen], 0.5 µL of forward and 0.5 µL of reverse primers, 2 
µL of cDNA and 9.5 µL RNase-free water [Qiagen, UK] to make a final volume of 
25 µL.  The thermal cycle was as follows: 2 minutes at 55°C, 10 minutes at 95°C 
followed by 40 cycles of 30 seconds at 95°C, and 60 seconds at 60°C.  Each 
parameter was analysed in duplicate on three independent occasions using the 
MxProP Quantitative PCR machine and MxProP 3000 software [Stratgene, 
Amsterdam, Netherlands].  The expression of genes of interest was normalised to 
the housekeeping gene GAPDH using the 2−ΔCt method, and then the relative 
expression of gene transcripts to the media control was quantified using the 2-ΔΔCt 
method (Livak and Schmittgen, 2001). 
 
Table 2.1: Primer sequences used in real-time quantitative PCR 
 
Target Primer sequence (5’-3’) Reference 
 Feline IL-8 F - TCCAAGCTGGTTGTTGCTCT 
R - TGCACTGGCATCGAAGTTCT 
In-house 
Human IL-8 F - CAGAGACAGCAGAGCACACAA 
R - TTAGCACTCCTTGGCAAAAC 
(Ramage et al., 2012) 
GAPDH F - GAGCTGAATGGGAAGCTCAC 
R - CGTATTTGGCAGCTTTCTCC 
(Dolieslager et al., 
2013) 
    F, forward; R, reverse. 
 
2.2.11 Enzyme-linked immunosorbent assay (ELISA) 
 
Supernatants from each cell line (THP1-XBlueTM and SCCF1) challenged with a 
panel of FCGS-associated bacteria for 24 h were retained to assess the release of 
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pro-inflammatory protein by ELISA.  ELISA kits for human [Peprotech, London, UK] 
and feline [R&D Systems, Abingdon, UK] interleukin-8 (IL-8) were used according 
to manufacturer’s instructions.  All incubations were carried out at room 
temperature.  A standard curve was constructed by plotting the mean absorbance 
for each standard against the IL-8 concentration and R-squared was calculated.  
Results were determined using a 4-parameter curve fit to determine the 
concentration of protein IL-8 released in samples tested.  All reactions were 
performed in duplicate on three separate occasions. 
 
2.2.11.1 Human IL-8 ELISA 
 
A human IL-8 ELISA kit was used to detect IL-8 release from human THP1-XBlueTM 
cells following bacterial stimulation.  Capture antibody (0.5 µg/mL) was prepared 
in PBS and 100 µL added to wells of Corning® 96-well high binding microplates 
[Sigma-Aldrich].  Plates were sealed and incubated overnight.  Contents were then 
discarded and plates washed with 300 µL of PBS containing 500 µL Tween20 
[Sigma-Aldrich] per litre.  Plates were blocked with 300 µL of block buffer 
containing 1% bovine serum albumin (BSA) in PBS for 1 h to block non-specific 
binding.  Plates were washed and 100 µL of each sample was loaded in triplicate.  
In addition, standards of known concentrations of IL-8 (15.6 to 1000 pg/mL) were 
included on each plate in duplicate and incubated for 2 h.  Contents were 
discarded and 100 µL of detection antibody (0.5 µg/mL) was added to each well 
containing sample or standard and incubated for a further 2 h.  Next, plates were 
washed and 100 µL of a 1:2000 dilution of avidin-HRP conjugate in assay diluent 
(0.05% Tween20, 0.1% BSA in PBS) was added to wells and incubated for 30 
minutes.  Finally, contents were discarded and 100 µL of 3,3’,5,5’-tetra-
methylbenzide (TMB) [Sigma-Aldrich] was added to each well and incubated in the 
dark for 20 minutes before the addition of 100 µL of 1 mM HCl to stop the reaction.  
The absorbance was read using the FLUOstar Omega plate reader (BMG Labtech, 
Ortenberg, Germany) at 405 nm with a 650 nm wavelength correction.    
 
2.2.11.2 Feline IL-8 ELISA 
 
A feline IL-8 ELISA kit was used to assess the release of IL-8 from feline SCCF1 cells 
following bacterial stimulation.  Briefly, 100 µL of capture antibody (4 µg/mL) 
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prepared in PBS was added to Corning® 96-well high binding microplates and 
incubated overnight.  Contents were discarded and plates washed with 400 µL of 
wash buffer (0.05% Tween20 in PBS).  Plates were then blocked with reagent 
diluent (1% BSA in PBS) for 1 h to prevent non-specific protein interactions.  Plates 
were washed and 100 µL of each sample was loaded in duplicate as well as 
standards of known concentrations of IL-8 ranging from 62.5 to 4000 pg/mL and 
incubated for 2 h.  Contents were again discarded and 100 µL of detection 
antibody (500 ng/mL) prepared in reagent diluent was added to wells with samples 
and standards and incubated for 2 h.  Plates were washed and 100 µL of 
streptavidin-HRP (diluted 1:200 with reagent diluent) was added to each well and 
incubated for 20 minutes.  Finally, plates were washed and 100 µL of substrate 
solution TMB was added to wells and incubated in the dark for 20 minutes, and 
then 50 µL of 1mM HCl was added to stop the reaction.  The absorbance was 
measured at 450 nm with a 570 nm wavelength correction.  
 
2.2.12 Statistical analysis 
 
Graph production and statistical analysis were performed using GraphPad Prism 
(version 5; La Jolla, USA).  Data which followed a normal distribution was analysed 
by using a one-way analysis of variance (ANOVA) to investigate significant 
differences between the mean of two or more independent groups.  A two-way 
ANOVA was used to compare the mean of two or more independent groups at 
multiple time points.  A Bonferroni correction (two-way ANOVA) was used to 
determine statistically significant differences between groups.  A Dunnett’s post-
test (one-way ANOVA) was used to measure significant differences between 
independent groups and the control group.  Statistical significance was achieved 
at p<0.05 for all analyses. 
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2.3 Results 
 
2.3.1 THP1-XBlueTM TLR activation is influenced by concentration-
dependent stimulation with FCGS putative pathogens 
 
An in vitro model system was developed involving the stimulation of cell lines with 
bacteria involved in FCGS to measure the ability of these bacteria to induce an 
inflammatory response within the host.  A human cell line containing an NF-κB-
inducible secreted embryonic alkaline phosphatase (SEAP) reporter construct was 
exposed to varying concentrations of T. forsythia and P. circumdentaria (believed 
to be key pathogens in FCGS), Pasteurella multocida species (putative pathogens 
in FCGS), B. zoohelcum (a representative feline commensal bacterium) and P. 
gingivalis (a major human periodontal pathogen).  This allowed for the ability of 
FCGS-associated bacteria to activate toll-like receptors (TLRs), and consequently 
promote host inflammation, to be assessed. THP1-XBlueTM cells incubated without 
bacteria were used as a cells only control (MOI of 0). 
 
Following 4 hour stimulations, there were significant increases in the level of SEAP 
production in cells exposed to T. forsythia and P. gingivalis, with the cell only 
control (MOI of 0) absorbance of 0.04 and 0.05 increasing to 1.13 (p<0.001) and 
0.34 (p<0.001), respectively, at an MOI of 200 (Figure 2.1).  Following 24 hour 
stimulations, there were significant increases in the level of SEAP release in cells 
exposed to T. forsythia (MOI 0, 0.06; MOI 200, 2.06; p<0.001), P. multocida subsp. 
multocida (MOI 0, 0.25; MOI 200, 1.31; p<0.001), P. multocida subsp. septica (MOI 
0, 0.41; MOI 200, 1.29; p<0.001), and P. gingivalis (MOI 0, 0.06; MOI 200, 1.30; 
p<0.001) at an MOI of 200 compared to an MOI of 0.  There was also a notable 
increase in SEAP production in cells following exposure to an MOI of 200 for 24 
hours compared to 4 hours in T. forsythia (4 h, 1.13; 24 h, 2.06; p<0.001) , P. 
multocida subsp. multocida (4 h, 0.40; 24 h, 1.31; p<0.001), P. multocida subsp. 
septica (4 h, 0.40; 24 h, 1.29; p<0.001) and P. gingivalis (4 h, 0.34; 24 h, 1.30; 
p<0.001).  Although there appeared to be an increase in SEAP production in the 
24 h supernatant with P. circumdentaria, no significant differences in were shown 
in cells following exposure to P. circumdentaria or B. zoohelcum. 
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2.3.2 THP1-XBlueTM cell IL-8 mRNA expression is influenced by 
concentration-dependent stimulation with FCGS putative 
pathogens 
  
To further investigate the response of the THP1-XBlueTM cells to FCGS-associated 
bacteria, the impact of varying MOIs of bacteria of interest on the regulation of 
pro-inflammatory mediator IL-8 was assessed.  IL-8 is a key mediator of 
periodontal inflammation and so was an appropriate indicator for chronic 
inflammation in this study. First, THP1-XBlueTM cell IL-8 mRNA expression, 
normalised to the housekeeping gene GAPDH, was measured (Figure 2.2). 
Figure 2.1: SEAP expression of THP1-XBlueTM cells following exposure to 
bacterial panel of interest 
THP1-XBlueTM cells were seeded at the concentration of 2x105 cells/mL in a 96-well plate 
for SEAP studies.  Cells were exposed to heat-killed bacteria ([A] Tannerella forsythia [B] 
Pasteurella multocida subsp. multocida [C] Pasteurella multocida subsp. septica [D] 
Porphyromonas circumdentaria [E] Porphyromonas gingivalis [F] Bergeyella zoohelcum) 
at various multiplicities of infection (M.O.I) (0-200) for a period of 4 hours and 24 hours.  
QUANTI-BlueTM assay was then used to measure SEAP with colour development measured 
at an absorbance wavelength of 630 nm.  All groups were assayed in triplicate on three 
separate occasions.  Statistical analysis was performed using two-way ANOVA and 
Bonferroni post-hoc test to compare all groups. Data represents mean ± SD (Comparison 
to cells only (0) § p<0.05, §§ p<0.01, §§§ p<0.001) (4 hours vs. 24 hours **p<0.01, 
***p<0.001). 
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Following 24 h exposure, THP1-XBlueTM IL-8 expression was significantly up-
regulated in cells following exposure to T. forsythia (168.78-fold increase; 
p<0.001), P. circumdentaria (3.07-fold increase; p<0.05), and P. gingivalis 
(199.57-fold increase; p<0.001) at an MOI of 200 compared to the cell only control 
(MOI 0).  Cells also showed an increase in IL-8 mRNA expression when stimulated 
with T. forsythia at a lower MOI of 50 (56.88-fold increase; p<0.05) and 100 
(101.44-fold increase; p<0.01). No statistically significant differences were 
observed in gene expression following exposure to Pasteurella species and B. 
zoohelcum species at any MOI; however, there was a notable trend of a 
concentration-dependent increase in IL-8 expression from all bacteria at an MOI 
of 200 compared to 0.   
 
Figure 2.2: THP1-XBlueTM cell IL-8 mRNA expression following exposure to 
bacterial panel of interest 
THP1-XBlueTM cells were seeded at the concentration of 2x105 cells/mL in a 96-well plate.  
Cells were exposed to heat-killed bacteria ([A] Tannerella forsythia [B] Pasteurella 
multocida subsp. multocida [C] Pasteurella multocida subsp. septica [D] Porphyromonas 
circumdentaria [E] Porphyromonas gingivalis [F] Bergeyella zoohelcum) at various 
multiplicities of infection (0-200) for 24 h.  RT-qPCR was performed using SYBR® green to 
determine IL-8 relative expression, normalised to GAPDH. Samples were assayed in 
duplicate on three independent occasions. Statistical analysis was performed using one-
way ANOVA and Dunnett’s post-hoc test. Data represents mean ± SD (*p<0.05, **p<0.01, 
***p<0.001). 
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2.3.3 THP1-XBlueTM cell IL-8 protein release is influenced by 
concentration-dependent stimulation with FCGS putative 
pathogens 
 
Due to the previous data (section 2.3.2) showing an altered IL-8 mRNA expression 
in THP1-XBlueTM cells in response to FCGS-associated bacteria, protein release was 
then examined. Levels of IL-8 protein in cell culture supernatants following 24 h 
stimulation with the bacterial panel of interest were assessed (Figure 2.3).     
 
THP1-XBlueTM cells incubated without bacteria were used as a cells only control 
(MOI 0).  A significant increase in IL-8 protein release was shown in cells stimulated 
with T. forsythia at an MOI of 100 (835.99 pg/mL; p<0.01) and 200 (2542.61 
pg/mL; p<0.001) compared to the cells only control of 10.20 pg/mL.  There was 
also a significant increase in cell IL-8 following exposure to P. multocida subsp. 
multocida at 50 (262.49 pg/mL; p<0.01), 100 (1132.19 pg/mL; p<0.0001), and 200 
(3441.62 pg/mL; p<0.001) MOI compared to the control of 15.44 pg/mL.  Exposure 
to P. gingivalis showed a large significant increase in IL-8 release at all MOIs, with 
3652.62 pg/mL present at an MOI of 200 (p<0.001).  A significant increase in IL-8 
production was shown in cells following exposure to P. multocida subsp. septica 
(1421.41 pg/mL; p<0.01) and B. zoohelcum (104.64 pg/mL; p<0.001) at an MOI of 
200 only.  No significant increase in protein release was noted following exposure 
to P. circumdentaria. 
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Figure 2.3: THP1-XBlueTM cell IL-8 protein response to bacterial panel of 
interest 
THP1-XBlueTM cells were seeded at the concentration of 2x105 cells/mL in a 96-well plate.  
Cells were exposed to heat-killed bacteria ([A] Tannerella forsythia [B] Pasteurella 
multocida subsp. multocida [C] Pasteurella multocida subsp. septica [D] Porphyromonas 
circumdentaria [E] Porphyromonas gingivalis [F] Bergeyella zoohelcum) at various 
multiplicities of infection (0-200) for 24 h.  IL-8 protein release in culture supernatants 
was measured by ELISA. Samples were assayed in duplicate on three independent 
occasions.  Statistical analysis was performed using one-way ANOVA and Dunnett’s post-
hoc test. Data represents mean ± SD (**p<0.01, ***p<0.001). 
 
 
2.3.4 SCCF1 cell IL-8 mRNA expression is influenced by 
concentration-dependent stimulation with FCGS-associated 
bacteria 
 
Next, it was investigated whether the FCGS-associated bacteria evoked a similar 
biological response in a feline oral squamous cell carcinoma cell line, SCCF1, by 
measuring changes in pro-inflammatory mediator IL-8. 
 
The IL-8 gene expression from SCCF1 cells following exposure to the bacterial 
panel of interest was firstly measured, as shown in Figure 2.4.  All bacteria showed 
to significantly increase IL-8 expression in cells at an MOI of 200 compared to the 
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cell only control, with an 8.52-fold increase from T. forsythia (p<0.001); 13.53-
fold increase from P. multocida subsp. multocida (p<0.001); 4.81-fold increase 
from P. multocida subsp. septica (p<0.05); 38.89-fold increase from P. 
circumdentaria (p<0.001); 2.77-fold increase from P. gingivalis (p<0.001); and 
47.46-fold increase from B. zoohelcum (p<0.01).  IL-8 expression was significantly 
up-regulated following exposure to P. circumdentaria at the lowest MOI (25) of all 
the bacteria (p<0.01).  
 
 
 
Figure 2.4: SCCF1 cell IL-8 mRNA expression following exposure to bacterial 
panel of interest 
SCCF1 cells were seeded at the concentration of 2x105 cells/mL in a 96-well plate.  Cells 
were exposed to heat-killed bacteria ([A] Tannerella forsythia [B] Pasteurella multocida 
subsp. multocida [C] Pasteurella multocida subsp. septica [D] Porphyromonas 
circumdentaria [E] Porphyromonas gingivalis [F] Bergeyella zoohelcum) at various 
multiplicities of infection (0-200) for 24 h.  RT-qPCR was performed using SYBR® green to 
determine IL-8 relative expression, normalised to GAPDH. Samples were assayed in 
duplicate on three independent occasions. Statistical analysis was performed using one-
way ANOVA and Dunnett’s post-hoc test. Data represents mean ± SD (*p<0.05, **p<0.01, 
***p<0.001). 
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2.3.5 SCCF1 cell IL-8 protein release is influenced by 
concentration-dependent stimulation with FCGS-associated 
bacteria 
 
As IL-8 mRNA expression was shown to be generally up-regulated in SCCF1 cells 
following exposure to FCGS-associated bacteria (Figure 2.4), the production of 
this chemokine by host cells was further investigated by ELISA. 
 
IL-8 release from SCCF1 cells in response to bacterial stimulation was synonymous 
to IL-8 release from the human THP1-XBlueTM cell line, with an increasing IL-8 
concentration found in supernatants as MOI increased.  A significant increase in 
IL-8 protein was measured following stimulation with T. forsythia (4382.34 pg/mL; 
p<0.001), P. multocida subsp. multocida (3049.44 pg/mL; p<0.001), P. multocida 
subsp. septica (4888.57 pg/mL; p<0.001), P. circumdentaria (3988.95 pg/mL; 
p<0.05), P. gingivalis (6175.58 pg/mL; p<0.05), and B. zoohelcum (4855.11 
pg/mL; p<0.001) at an MOI of 200 compared to the cells only control (MOI 0) 
(Figure 2.5).  IL-8 protein release in cells was also increased after exposure with 
an MOI of 100 of T. forsythia (p<0.05), P. multocida species (p<0.05) and B. 
zoohelcum (p<0.001). 
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Figure 2.5:  SCCF1 cell IL-8 secretion following exposure to bacterial panel of 
interest 
SCCF1 cells were seeded at the concentration of 2x105 cells/mL in a 96-well plate and 
incubated at 37°C in 5% CO2 for 24 h.  Cells were exposed to heat-killed bacteria ([A] 
Tannerella forsythia [B] Pasteurella multocida subsp. multocida [C] Pasteurella 
multocida subsp. septica [D] Porphyromonas circumdentaria [E] Porphyromonas gingivalis 
[F] Bergeyella zoohelcum) at various multiplicities of infection (0-200) for 24 h.  IL-8 
protein release in culture supernatants was measured by ELISA.  Samples were assayed in 
duplicate on three separate occasions.  Statistical analysis was performed using one-way 
ANOVA and Dunnett’s post-hoc test. Data represents mean ± SD (*p<0.05, ***p<0.001). 
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2.4 Discussion 
 
While the aetiology of FCGS is believed to be multifactorial, it is thought that the 
dysbiosis of interactions between oral plaque bacteria and the host immune 
system is a key contributor to the chronic inflammation present during FCGS.  
Specific bacteria, as seen in periodontal disease, have been identified as more 
predominant within oral communities in diseased cats with abnormal levels of 
inflammation, including Pasteurella species (Dolieslager et al., 2011).  In this 
chapter, the interactions between FCGS-associated bacteria and host cells have 
been investigated in order to establish a greater understanding of the cell 
response to bacteria of interest, and how the presence of specific bacteria may 
modulate the immune response during disease.  
 
The key finding was that both human and feline host cell lines demonstrated a 
distinct IL-8 gene and protein response to varying concentrations of heat-killed 
FCGS-associated bacteria, particularly in response to bacteria thought to be 
putative pathogens in disease. This result showed the immune function 
consequences of feline bacterial species of differing pathogenicity and their 
potential to contribute to the chronic inflammation that is evident in FCGS. 
 
The data, firstly, showed the changes in TLR activation when THP1-XBlueTM cells 
were exposed to FCGS-associated bacteria.  THP1-XBlueTM cells could be used in 
this study as a comparative positive control as it is already known that P. gingivalis 
is a major periodontal pathogen in human oral disease (Hajishengallis et al., 
2012).  Pathogen-associated molecules are recognised by several sensors of the 
innate immunity, including TLRs (Akira and Takeda, 2004).  TLRs can mediate the 
inflammatory response when activated by specific pathogens.  Thus, various 
enzymatic bio-assays have been developed which co-express a TLR-inducible 
reporter gene encoding SEAP, which allows TLR stimulation to be conveniently 
monitored by using a phosphatase detection assay.  In this study, TLR activation, 
represented by levels of SEAP production, was significantly increased in cells 
exposed to feline putative pathogens T. forsythia and P. multocida species as well 
as human pathogen P. gingivalis.  A study by Dolieslager et al. (2013) found that 
cats harbouring T. forsythia had significant increases in TLR2, TLR4, TLR7 and 
TLR9 compared to cats in which this bacterial species was absent.  As T. forsythia 
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showed the greatest influence on TLR activation in this study, followed by P. 
multocida species which have shown to be highly prevalent during disease, this 
suggests that these bacteria may be of importance in stimulating a host immune 
response to FCGS.   
 
Moreover, THP1-XBlueTM cells showed significantly increased IL-8 gene expression 
in response to T. forsythia, P. circumdentaria and P. gingivalis and significantly 
increased levels of IL-8 protein were present in response to T. forsythia, P. 
multocida subsp. multocida, P. multocida subsp. septica, P. gingvalis and B. 
zoohelcum.  IL-8 acts by recruiting immune cells such as neutrophils and T 
lymphocytes to the site of infection and stimulates phagocytosis, and is therefore 
widely acknowledged as a causative agent of inflammation in both humans and 
felines (Shahzad et al., 2010; Alavi-Moghaddam et al., 2011).  As T. forsythia and 
P. gingivalis are known pathogens in human oral disease, the THP1-XBlueTM 
immune response observed was as expected in this study.  A previous study has 
shown T. forsythia contains a PrtH protein that is able to stimulate inflammation 
by inducing the production of IL-8 (Ksiazek et al., 2015).  The notable increase in 
TLR activation by T. forsythia and P. multocida species and concurrent increase 
in IL-8 protein release in this study suggests these bacteria may be key in eliciting 
an innate immune response during disease and could be significant in the 
aetiopathogenesis of FCGS. 
 
Furthermore, the inflammatory response to FCGS-associated bacteria was 
investigated in a feline squamous carcinoma cell line, SCCF1.  All bacteria tested 
(key pathogens, putative pathogens and commensal) elicited an increase in IL-8 
mRNA expression at an MOI of 200, as well as an increase in IL-8 protein expression 
which increased with an increasing concentration of bacteria applied.  Previous 
research has discovered that P. multocida species are highly prevalent in the 
feline oral cavity during FCGS, comprising 51.8% of the bacterial population and 
therefore considered significant in disease  (Dolieslager et al., 2011).  These 
results suggest that P. multocida species can stimulate pro-inflammatory IL-8 gene 
expression and protein production in a feline cell line and therefore may play a 
key role in stimulating the chronic inflammation found during disease.  Moreover, 
Dolieslager et al. (2011) found B. zoohelcum to be highly prevalent in the oral 
cavity of healthy cats compared to those with FCGS; however, the data in the 
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current study suggests that B. zoohelcum is capable of stimulating an 
inflammatory response during disease.   
 
While this model proved to demonstrate the initial innate cell responses to 
putative bacteria in this study, it is important to consider that heat-killed bacteria 
were used to stimulate cells due to the ability of many live bacteria to modulate 
pro-inflammatory cytokines and chemokines.  It has been shown that P. gingivalis 
can subvert the host proinflammatory response, through lysine gingipain, by direct 
degradation of chemokines such as IL-8 (Stathopoulou et al., 2009).  One study 
has also observed that differing levels of pro-inflammatory cytokines were induced 
in blood cultures by live Streptococcus suis compared to the heat-killed bacterium 
(Segura et al., 2006).  Therefore, the host response to heat-killed bacteria in this 
study may not reflect the inflammatory response induced by live bacteria. 
 
In summary, focusing on how specific bacteria may differentially modulate the 
host immune response is crucial to understanding the abnormal inflammatory 
levels evident in FCGS.  It would be interesting to use this model further to test 
FCGS-associated bacteria in combination, or within a biofilm to measure the 
differences in immune response. 
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3 Development of an in vitro FCGS biofilm model for 
therapeutic testing 
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3.1 Introduction and Aims 
 
The human oral microbiome is known to play a significant role in human health 
and disease.  While the feline oral microbiome is less well studied, it is thought 
that over 400 bacterial species associated with the feline oral cavity contribute 
to feline oral health (Adler et al., 2016). 
 
Bacterial communities that reside in the oral cavity form complex biofilms 
(plaque) on teeth and soft gingival tissues (Zijnge et al., 2010).  Within the 
biofilm, bacteria are more resistant to antibiotics and antimicrobials, and are 
highly capable of evading host defences (Bjarnsholt, 2013).  As microbial 
communities can readily alter the local environment, biofilm composition can shift 
to an increasing proportion of disease-associated bacteria which ultimately leads 
to disease such as periodontitis (Berezow and Darveau, 2011).  It is thought this 
microbial dysbiosis may also occur in the feline oral cavity during the development 
of FCGS.  Due to the large diversity of bacteria found in dental plaque, studying 
the roles and impact of bacteria within oral biofilms has proved difficult.  
Therefore, a variety of in vitro biofilm models have previously been created to 
replicate a diseased microbial environment within the oral cavity, allowing the 
study of bacterial interactions within biofilms and the evaluation of orally relevant 
antimicrobial compounds. 
 
Due to the complex nature of FCGS, an adequate treatment is not yet available.  
A first-line treatment for all affected cats involves the improvement of basic oral 
hygiene in attempt to reduce the oral antigen burden as well as antibiotics in some 
cases to control excessive inflammation.  However, in almost all cases, first-line 
treatment is a short-term resolution, and diseased teeth will then be extracted to 
reduce the chronic inflammation.  Chlorhexidine (CHX) is also used as an effective 
post-op plaque control, however, reported prolonged use of CHX in studies of 
human oral disease has shown adverse reactions such as pain of the oral mucosa 
and anaphylaxis (Frank et al., 2001, Dyer et al., 2013).  Furthermore, CHX does 
not always prove to be entirely effective or suitable for all cats (Lobprise and 
Dodd, 2018).   
 
Discovering alternative compounds which have the same, or greater, antimicrobial 
potency of CHX but low toxicity is of importance in the search for appropriate 
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treatments to reduce the bacterial burden during FCGS.  Antimicrobials such as 
CHD-FA and xylitol have both previously shown to be an effective treatment option 
used on multi-species biofilms devised to mimic human oral disease (Badet et al., 
2008; Sherry et al., 2013).  Berberine, an isoquinoline alkaloid, has also shown to 
have anti-microbial properties on single-species biofilms of Pseudomonas and 
Staphylococcus species (Aswathanarayan and Vittal, 2018; Wang et al., 2009).  
These studies highlight the potential of these novel compounds to inhibit biofilm 
activity, and therefore testing these compounds on an FCGS biofilm was worth 
investigation in this study.  Moreover, ubiquinol is an active ingredient found in 
the anti-microbial and anti-inflammatory product, Oralmat®, so was of interest to 
discover the antimicrobial potential of this compound.   
 
Therefore, the aim of this study was to create an in vitro multi-species biofilms 
model to mimic disease-associated plaque, containing bacteria which are orally 
relevant to FCGS, which could be used to test the effect of various novel anti-
microbial compounds. 
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3.2 Materials and Methods 
 
3.2.1 Bacterial culture and standardisation 
 
A multispecies biofilm model consisting of 10 bacterial species associated with 
FCGS was developed for antimicrobial testing (Dolieslager et al., 2011).  P. 
multocida subsp. multocida, P. multocida subsp. septica, B. zoohelcum, P. 
circumdentaria and T. forsythia were cultured and standardised as previously 
described in 2.2.1.  Additionally, Streptococcus mitis NCTC 12261, Streptococcus 
intermedius ATCC 27335, and Streptococcus oralis ATCC 35037 were grown and 
maintained at 37°C on CBA in 5% CO2.  Actinomyces naeslundii DSMZ 17233 and 
Fusobacterium nucleatum DSMZ 10953 were cultured at 37°C on FAA under 
anaerobic conditions.       
 
S. mitis, S. intermedius, and S. oralis were propagated in 10 mL tryptic soy broth 
[Sigma-Aldrich].  A. naeslundii and F. nucleatum were grown in 10 mL of 
Schaedler’s anaerobic broth under anaerobic conditions.  Cultures were grown for 
24-48 h at 37°C as necessary and washed as previously described in 2.2.1.  All 
bacteria were then standardised and adjusted to a final working concentration of 
1 x 108 cells/mL for downstream biofilm development and sessile susceptibility 
testing.    
 
3.2.2 Biofilm growth medium 
 
All biofilm cultures were initially grown using artificial saliva (AS) as previously 
described (Pratten et al., 1998).  This was comprised of porcine stomach mucins 
(0.25% w/v) [Sigma-Aldrich], sodium chloride (0.35 w/v) [VWR, Leuven, Belgium] 
potassium chloride (0.02 w/v) [VWR], calcium chloride dihydrate (0.02 w/v) 
[VWR], yeast extract (0.2 w/v) [Formedium, Hunstanton, UK], lab lemco powder 
(0.1 w/v) [Oxoid] and proteose peptone (0.5 w/v) [Sigma-Aldrich] in ddH2O 
[Thermo Scientific]. Urea [Sigma-Aldrich] was diluted in ddH2O (40% w/v) and 
added to a final concentration of 0.05% (v/v) in AS. 
 
A second medium was also used to grow biofilms during this study.  This consisted 
of Todd Hewitt broth (THB) [Sigma-Aldrich] supplemented with 10 µg/mL hemin 
[Sigma-Aldrich] and 2 µg/mL menadione [Sigma-Aldrich].  To make a working 
 47 
broth, the supplemented THB was added to an equal volume of RPMI-1640.  
Bacterial growth and biofilm formation were not affected when cultured in the 
THB: RPMI medium. 
 
3.2.3 Multi-species biofilm culture (10 species) 
 
An in vitro multi-species biofilm was developed to represent and recapitulate the 
diseased microbial environment present in the oral cavity during FCGS. The 10 
species model consisted of S. mitis, S. intermedius, S. oralis, B. zoohelcum, P. 
multocida subsp. multocida, P. multocida subsp. septica, A. naeslundii, F. 
nucleatum, T. forsythia and P. circumdentaria.  Biofilms were prepared in 24-well 
plates [Corning, NY, USA] containing ThermanoxTM coverslips (13 mm diameter) 
[Fisher Scientific, Loughborough, UK].  For the addition of each bacterial species 
to the biofilm, bacterial suspensions were standardized to 1 x 107 CFU/mL in 500 
µL of THB: RPMI medium.  Firstly, S. mitis, S. intermedius, and S. oralis were 
added together and incubated at 37°C in 5% CO2 for 24 hours.  Next, the 
supernatant was removed and B. zoohelcum, P. multocida subsp. multocida and 
P. multocida subsp. septica standardised in THB: RPMI were added to the biofilms 
and grown for 24 hours at 37°C in 5% CO2.  On the third day, the supernatant was 
again removed and A. naeslundii, F. nucleatum, T. forsythia and P. 
circumdentaria standardised in THB: RPMI were added before the biofilms were 
incubated anaerobically at 37°C for a further 4 days.  Each day, the supernatants 
were removed and fresh THB: RPMI added.  
 
Biofilms were either used for testing directly after culture, or the supernatant was 
removed and biofilms were washed with PBS before storage at -80°C until 
required.  Frozen biofilms were revived by the addition of 500 µL of THB: RPMI 
and incubation for 24 h in the anaerobic cabinet before experimental use. 
 
3.2.4 Investigating sialidase inhibitors as a novel treatment option  
 
3.2.4.1 Bacterial sialidase activity 
 
The sialidase activity of FCGS putative pathogens (P. multocida subsp. multocida, 
P. multocida subsp. septica, P. circumdentaria and T. forsythia) was determined.  
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Firstly, 1 mL of 1 x 106 CFU/mL of each bacterium was added to a 0.1 mM 4-
methylumbelli-feryl N-acetyl-α-D-neuraminic acid (MUNANA) sodium salt 
[Carbosynth Limited, Compton, UK] solution to create a reaction mix.  The 
samples were incubated for 24 h in aerobic (P. multocida species) or anaeorobic 
(P. circumdentaria and T. forsythia) conditions, with the transfer of 50 µl of each 
reaction mix to separate wells of a clear-bottomed black 96-well plate following 
incubation period.  The reaction was stopped by the addition of 75 µL of 100 mM 
sodium carbonate buffer [Sigma-Aldrich] to each well and then the fluorescence 
measured at 355 nm and 460 nm on a microplate reader.  
 
3.2.4.2 Bacterial sialidase inhibition 
 
Two potential sialidase inhibitors were investigated in this study: a novel plant 
alkaloid, berberine, which has previously shown to inhibit sialidase activity in 
various strains of influenza virus (Enkhtaivan et al., 2017), and sialic acid 
analogue, 2-deoxy-2,3-dehydro-N-acetyleneuraminic acid (DANA), which has 
shown to inhibit viral, bacterial and mammalian sialidases (Meindl and Tuppy, 
1969; Burmeister et al., 1993).  A 40 mM stock solution of inhibitor was serially 
diluted to 10 µm in PBS.  Each bacterial species was standardized to 1 x 106 
CFU/mL and 450 µL was added each to 50 µL of inhibitor and incubated for 1 h in 
appropriate conditions.  Following incubation, 225 µL of 0.1 mM MUNANA was 
added to create the reaction mix.  Samples were then incubated for up to 24 h, 
with transfer of sample to separate wells of a clear-bottomed black 96-well plate 
at time intervals of 0, 1, 2, 3, 4, 22 and 24 h during incubation.  The reactions 
were quenched at each time point by the addition of 75 µL of 100 mM sodium 
carbonate buffer, and fluorescence measured at 355 nm and 460 nm on a 
microplate reader. 
 
3.2.5 Antibacterial susceptibility testing of multi-species biofilm 
 
During this study, four active compounds were tested to determine the 
antibacterial potential on FCGS biofilm cells.  The compounds included xylitol 
[Sigma-Aldrich] which has shown to inhibit human oral multi-species biofilm 
growth (Badet et al., 2008); carbohydrate-derived fulvic acid (CHD-FA) [Fulhold 
Ltd, Cape Town, South Africa] which has shown to be effective against a multi-
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species periodontal biofilm (Sherry et al., 2013); berberine [Sigma-Aldrich] which 
is a potential sialidase inhibitor and has shown anti-microbial activity 
(Aswathanarayan and Vittal, 2018); and ubiquinol [Sigma-Aldrich] which is an 
active agent in the natural anti-inflammatory Oralmat® product.  Chlorhexidine 
(CHX) [Sigma-Aldrich] at 0.2% was also used as a positive control.  
 
For testing on multi-species biofilms, biofilms were grown as previously described 
in section 3.2.3.  Compounds were prepared at a range of concentrations for anti-
microbial testing, according to inhibitory concentrations found in literature.  
Xylitol was prepared at 0.25, 0.5, 1, and 5% (w/v).  CHD-FA was prepared at 0.25, 
0.5, and 0.8% (v/v).  Berberine and ubiquinol were prepared at 50, 100, and 200 
µg/mL.  Mature biofilms were treated for 5 minutes (CHD-FA, xylitol, ubiquinol) 
or 24 h (berberine) with each concentration of compound before the addition of 
neutralising buffer to stop the agents from acting on the biofilms for longer than 
desired.  Biofilms were then washed with PBS before further downstream testing 
to measure for disruption of biofilms.  The experiment was carried out in triplicate 
on three independent occasions. 
 
3.2.6 alamarBlue® cell viability assay 
 
The resazurin-based solution alamarBlue® [Invitrogen] was used to measure multi-
species biofilm cell viability following treatments with each compound.  Following 
treatment, multi-species biofilms were carefully washed with PBS before the 
addition of alamarBlue® (at a 1:10 dilution in THB: RPMI medium) to each well.  
The alamarblue® is a colorimetric assay whereby a colour change (blue to pink) 
occurs as a result of an oxidation/reduction reaction based upon cellular 
metabolic activity.   The alamarBlue® was incubated for 1-2 hours under anaerobic 
conditions.  Following incubation, the fluorescence was read at 544 nm with a 
reference wavelength at 590 nm.  The mean fluorescence of each treatment group 
was used to calculate the percentage of cell viability compared to the untreated 
control as follows: percentage of cell viability = (Atreatment – Ablank) / (Acontrol – Ablank) 
x 100% (where, A = fluorescence).  Biofilms were washed with PBS and left to dry 
on the bench overnight for crystal violet assay, as described in section 3.2.8. 
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3.2.7 Biofilm quantification: Miles and Misra 
 
Live bacterial cells in the treated multi-species biofilms were quantified using the 
Miles and Misra method (Miles et al., 1938).  Briefly, treated biofilms (not used in 
cell viability or biomass testing) were removed from ThermanoxTM coverslips in a 
sonic bath at 35 kHz for 10 minutes in 1 mL of PBS.  Each inoculum was then 
serially ten-fold diluted from neat supernatant to 10-8 in PBS.  For each dilution, 
10 µL was drop-plated in triplicate on both CBA and FAA plates, left to dry on the 
bench for 30 minutes, and then cultured in the appropriate conditions for 24 and 
48 h, respectively.  Following incubation, colonies were then counted at each 
dilution where the number of colonies ranged between 30 – 300 and the colony-
forming units (CFU) were calculated as follows: CFU = no. of colonies / volume 
plated (mL) x dilution factor.   
 
3.2.8 Biofilm biomass quantification by crystal violet assay 
 
To quantify biofilm biomass following antimicrobial treatment, crystal violet (CV) 
assays were performed.  Five hundred microlitres of 0.05% (w/v) CV solution was 
added to each biofilm and incubated for 20 minutes at room temperature, 
allowing uptake of the dye.  The CV solution was then discarded and biofilms were 
carefully washed with water to remove any excess dye.  Next, 500 µL of 100% 
ethanol was added to biofilms and mixed thoroughly to release the CV dye before 
transferring 75 µL from each well to a fresh 96-well flat-bottomed plate.  Biofilm 
biomass was then measured by reading absorbance at 570 nm in a microtitre plate 
reader.  A negative control, containing media only, was included to allow for blank 
correction of all absorbance values.    
 
3.2.9 Statistical analysis 
 
Graph production and statistical analysis was carried out using GraphPad Prism 
(version 5; La Jolla, USA). Independent sample data was analysed using a one-way 
ANOVA.  A Dunnett’s post-test and Bonferroni correction for multiple comparisons 
was applied to the data where appropriate.  A p value of less than 0.05 was 
considered significant.  
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3.3 Results 
 
3.3.1 FCGS putative pathogens display sialidase activity 
 
Since bacterial sialidases are believed to play a role during bacterial colonisation 
and pathogenesis of mammalian mucosal surfaces, it is possible that bacterial 
sialidases are used in the oral cavity to enhance biofilm formation and bacterial 
survival. If present, the bacterial enzyme sialidase cleaves MUNANA into N-
acetylneuraminic acid and 4-methylumbelliferone, which is a fluorescent 
molecule.  The sialidase activity of putative pathogens of FCGS was investigated 
based on the measurement of fluorescence (Figure 3.1). 
 
A reaction mix control was included containing no bacteria.  A significant 
difference in sialidase activity was observed after 24 h between the control, with 
a fluorescence of 2432, and each bacterial species: P. multocida subsp. septica 
(22-fold increase; p<0.001), P. mutocida supsp. multocida (26-fold increase; 
p<0.001), T. forsythia (25-fold increase; p<0.001), and P. circumdentaria (4-fold 
increase; p<0.001).  Hence, P. circumdentaria displayed the lowest sialidase 
activity. 
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Figure 3.1: Sialidase activity of FCGS putative pathogens 
Bacteria were standardized to 1 x 106 CFU/mL before incubation with MUNANA for 24 h.  
Following 24 h, each reaction was quenched using sodium carbonate buffer and sialidase 
activity was determined by measuring fluorescence at 355 nm and 460 nm.  A control 
containing no bacterial cells was included. Statistical analysis was performed using one-
way ANOVA and Dunnett’s post-hoc test to compare the means of each species to the 
control group mean. Data represents mean ± SD (***p<0.001) of three independent 
experiments each performed in triplicate. 
 
 
3.3.2 Berberine treatment inhibits FCGS putative pathogen 
sialidase activity 
 
As the previous data (section 3.3.1) demonstrated that the putative pathogens of 
FCGS displayed sialidase activity, all species were then used to investigate the 
efficacy of a potentially natural sialidase inhibitor, berberine (Figure 3.2).  
Bacteria were incubated over 24 h with inhibitor and fluorescence was measured 
at specific time intervals.  A bacteria only control was included (0 µM berberine). 
 
At 24 h, following treatment with 5 µM berberine, there was a significant 
difference in the fluorescence of T. forsythia (41% decrease; p<0.05) compared 
to the bacteria only control (0 µM) which contained no inhibitor.  No significant 
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differences were shown between P. multocida subsp. septica, P. multocida subsp. 
multocida, or P. circumdentaria following treatment of 5 µM berberine compared 
to the bacteria only control.  At 24 h, following treatment with 20 mM berberine, 
there was a significant difference in the fluorescence of P. multocida subsp. 
septica (89% decrease; p<0.001), P. multocida subsp. multocida (87% decrease; 
p<0.001), P. circumdentaria (79% decrease; p<0.001) and T. forsythia (71% 
decrease; p<0.001) compared to the bacteria only control (0 µM).  There was a 
notable concentration-dependent effect on the sialidase activity of all bacteria 
following treatment with berberine for 24 hours. 
 
 
Figure 3.2: Sialidase activity of putative pathogens in response to berberine 
Bacteria ([A] Pasteurella multocida subsp. septica [B] Pasteurella multocida subsp. 
multocida [C] Porphyromonas circumdentaria [D] Tannerella forsythia) were 
standardized to 1 x 106 CFU/mL before incubation with MUNANA and a range of 
concentrations of berberine for 24 h.  At time intervals of 0, 1, 2, 3, 4, 22 and 24 h, each 
reaction was quenched using sodium carbonate buffer and sialidase activity was 
determined by measuring fluorescence at 355/460 nm.  A negative control containing no 
bacterial cells was included.  Samples were assayed in triplicate on three separate 
occasions.  Statistical analysis was performed using a one-way ANOVA with Bonferroni’s 
post-test.  Data represents mean ± SD (*p<0.05). 
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3.3.3 DANA treatment inhibits FCGS putative pathogen sialidase 
activity 
 
Another known synthetic sialidase inhibitor, 2-deoxy-2,3-dehydro-N-
acetyleneuraminic acid (DANA), was investigated for its potential to inhibit the 
sialidase activity of putative pathogens in FCGS (Figure 3.3).  The bacteria were 
incubated with inhibitor over 24 h with fluorescence measured at set time 
intervals.  A bacteria only control, containing no inhibitor, was included (0 µM 
DANA). 
 
Following 24 h, there showed to be a statistically significant decrease in the 
fluorescence of T. forsythia compared to the bacteria only control (0 µM) after 
incubation with the lowest concentration of DANA used (5 µM) (51% decrease; 
p<0.01).  No significant differences in fluorescence were observed for the P. 
mutocida species or P. circumdentaria at 24 h incubation with 5 µM DANA.  At 24 
h, following treatment with berberine at a concentration of 20 mM, there was a 
significant decrease in the fluorescence of P. multocida subsp. septica (80% 
decrease; p<0.0001), P. multocida subsp. multocida (60% decrease; p<0.01), and 
T. forsythia (74% decrease; p<0.001) compared to the bacteria only control.  DANA 
showed to have no effect on the sialidase activity of P. circumdentaria, with no 
statistically significant differences in fluorescence displayed at any concentration.  
DANA generally showed to inhibit sialidase activity in a concentration-dependent 
manner.  
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Figure 3.3: Sialidase activity of putative pathogens in response to DANA 
Bacteria ([A] Pasteurella multocida subsp. septica [B] Pasteurella multocida subsp. 
multocida [C] Porphyromonas circumdentaria [D] Tannerella forsythia) were 
standardized to 1 x 106 CFU/mL before incubation with MUNANA and a range of 
concentrations of DANA for 24 h.  At time intervals of 0, 1, 2, 3, 4, 22 and 24 h, each 
reaction was quenched using sodium carbonate buffer and sialidase activity was 
determined by measuring fluorescence at 355/460 nm.  A negative control containing no 
bacterial cells was included.  Samples were assayed in triplicate on three separate 
occasions. Statistical analysis was performed using a one-way ANOVA with Bonferroni’s 
post-test.  Data represents mean ± SD (*p<0.05). 
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3.3.4 Berberine treatment affects biofilm biomass 
 
To measure the antimicrobial potential of the actives, multi-species biofilms were 
developed containing the FCGS bacteria which may reside in a diseased feline oral 
cavity and contribute to pathogenicity.  Biofilms were treated with berberine for 
24 h before cell viability was assessed using alamarBlue® metabolic dye.  Biofilm 
biomass following treatment was measured using crystal violet dye, and the 
number of viable cells were counted using the Miles and Misra method (Figure 
3.4).  
 
As berberine was previously found to inhibit sialidase activity in FCGS-associated 
bacteria, the effect of berberine on the FCGS multi-species biofilm was then 
investigated.  Untreated and positive (0.2% CHX) controls were included for 
comparison.  Cell viability was presented as a percentage of the untreated 
control.  The viability of biofilms treated with various concentrations of berberine 
was not comparable to the killing effect of CHX, and no significant differences 
were found between concentrations despite a notable decrease in viability in the 
biofilm treated with 200 µM compared to 50 µM.  The biofilm biomass of the 
untreated control was 1.83, which was significantly decreased by 50 µM and 100 
µM to 1.35 (p<0.05) and 1.40 (p<0.01), respectively.  No significant differences in 
the number of CFUs were found following treatment with berberine at each 
concentration, however, there was a notable decrease in the number of live 
aerobic and anaerobic cells in biofilms treated with 200 µM berberine compared 
to the untreated control. 
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Figure 3.4: Biofilm viability and biomass following berberine treatment 
Multi-species biofilms containing FCGS-associated bacteria were grown on ThermanoxTM 
coverslips and treated with 50, 100 and 200 µg/mL berberine for 24 hours.  Biofilms were 
also treated with 0.2% (v/v) CHX used as a positive control.  Metabolic activity was 
measured using alamarBlue® and data presented as a percentage of the untreated control 
[A].  Biofilms were retained following treatment and biofilm biomass determined by 
staining with 0.05% (w/v) crystal violet solution and quantified spectrophotometrically by 
reading at 570 nm [B].  Bacteria were sonicated in PBS for 10 min and viable bacteria 
enumerated using Miles and Misra plate counting method on CBA and FAA plates 
supplemented with 5% horse blood [C].  All samples were assayed in triplicate, on three 
separate occasions. Statistical analysis was performed using a one-way ANOVA with 
Bonferroni’s post-test.  Data represents mean ± SD (*p<0.05).  
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3.3.5 CHD-FA treatment affects biofilm viability and biomass 
 
Due to its effectiveness on previous multispecies biofilm models, the anti-
microbial activity of CHD-FA was measured by testing on FCGS multi-species 
biofilms as described previously (section 3.3.4).  Mature biofilms were treated for 
5 minutes with CHD-FA before the addition of a neutralising buffer to stop the 
reaction (Figure 3.5).   
 
Following a 5-minute treatment, CHD-FA at 0.8% was shown to significantly reduce 
cell viability to less than 5.94% of the untreated control, comparable to the CHX 
treatment which reduced cell viability to 2.96%.  Biofilms treated with a 
concentration of 0.8% CHD-FA also displayed significantly decreased cell viability 
compared to 0.5% and 0.25%, with observed viability of 40.82% and 73.64%, 
respectively.  Compared to the untreated control (1.00), biofilm biomass was also 
shown to significantly decrease to 0.66 (p<0.05) and 0.71 (p<0.05) following 
treatment with 0.8% and 0.5% CHD-FA, respectively.  Moreover, treatment of 
biofilms with CHD-FA showed a concentration-dependent decrease in the number 
of viable aerobic and anaerobic CFUs, however this was not deemed statistically 
significant compared to the untreated control. 
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Figure 3.5: Biofilm viability and biomass following CHD-FA treatment 
Multi-species biofilms containing FCGS-associated bacteria were grown on ThermanoxTM 
coverslips and treated with 0.25% (v/v), 0.5% (v/v) and 0.8% (v/v) CHD-FA for 5 min.  
Biofilms were also treated with 0.2% (v/v) CHX used as a positive control.  Metabolic 
activity was measured using alamarBlue® and data presented as a percentage of the 
untreated control [A].  Biofilms were retained following treatment and biofilm biomass 
determined by staining with 0.05% (w/v) crystal violet solution and quantified 
spectrophotometrically by reading at 570 nm [B].  Bacteria were sonicated in PBS for 10 
min and viable bacteria enumerated using Miles and Misra plate counting method on CBA 
and FAA plates supplemented with 5% horse blood [C].  All samples were assayed in 
triplicate, on three separate occasions.  Statistical analysis was performed using a one-
way ANOVA with Bonferroni’s post-test.  Data represents mean ± SD (*p<0.05, **p<0.001).  
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3.3.6 Xylitol treatment does not affect FCGS biofilm viability or 
biomass 
 
Furthermore, using the multi-species biofilm model, the activity of xylitol was 
investigated and biofilm viability, biomass and CFU counts were measured 
following a 5-minute treatment (Figure 3.6).   
 
No significant difference in biofilm cell viability was discovered between biofilms 
treated with xylitol at various concentrations (0.25-5%), with viability found to be 
over 90% of the untreated control at all concentrations tested.  Similarly, biofilm 
biomass did not significantly change following treatment with a range of xylitol 
concentrations compared to the untreated control.  The number of CFUs counted 
were shown to be decreased when plated on CBA compared to FAA, indicating that 
xylitol may have slightly higher toxicity to aerobic bacteria in the biofilm, however 
this was not statistically significant.  
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Figure 3.6: Biofilm viability and biomass following xylitol treatment 
Multi-species biofilms containing FCGS-associated bacteria were grown on ThermanoxTM 
coverslips and treated with 0.25% (w/v), 0.5% (w/v), 1% (w/v) and 5% (w/v) xylitol for 5 
min.  Biofilms were also treated with 0.2% (v/v) CHX used as a positive control.  Metabolic 
activity was measured using alamarBlue® and data presented as a percentage of the 
untreated control [A].  Biofilms were retained following treatment and biofilm biomass 
determined by staining with 0.05% (w/v) crystal violet solution and quantified 
spectrophotometrically by reading at 570 nm [B].  Bacteria were sonicated in PBS for 10 
min and viable bacteria enumerated using Miles and Misra plate counting method on CBA 
and FAA plates supplemented with 5% horse blood [C].  All samples were assayed in 
triplicate, on three separate occasions.  Statistical analysis was performed using a one-
way ANOVA with Bonferroni’s post-test. 
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3.3.7 Ubiquinol treatment does not affect FCGS biofilm viability or 
biomass 
 
The anti-microbial potential of ubiquinol, an active component of Oralmat® anti-
inflammatory remedy, was investigated on the FCGS multi-species biofilm (Figure 
3.7).  Following a 5-minute treatment with ubiquinol, biofilms showed no 
significant differences in cell viability or between various concentrations tested.  
There was also no significant difference in the level of biofilm biomass of biofilms 
treated at each concentration of ubiquinol compared to the untreated control.  
There was a notable decrease in the number of live aerobic cells within biofilms 
treated with 50 and 200 µg/mL of ubiquinol compared to the untreated control, 
however this decrease was not found to be significant.  
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Figure 3.7: Biofilm viability and biomass following ubiquinol treatment 
Multi-species biofilms containing FCGS-associated bacteria were grown on ThermanoxTM 
coverslips and treated with 50, 100 and 200 µg/mL ubiquinol for 5 min.  Biofilms were 
also treated with 0.2% (v/v) CHX used as a positive control.  Metabolic activity was 
measured using alamarBlue® and data presented as a percentage of the untreated control 
[A].  Biofilms were retained following treatment and biofilm biomass determined by 
staining with 0.05% (w/v) crystal violet solution and quantified spectrophotometrically by 
reading at 570 nm [B].  Bacteria were sonicated in PBS for 10 min and viable bacteria 
enumerated using Miles and Misra plate counting method on CBA and FAA plates 
supplemented with 5% horse blood [C].  All samples were assayed in triplicate, on three 
separate occasions.  Statistical analysis was performed using a one-way ANOVA with 
Bonferroni’s post-test.  
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3.4 Discussion 
 
Within the oral cavity, bacteria are known to reside within multi-species biofilms, 
where changes in the composition of biofilm bacterial communities may disrupt 
host-microbial symbiosis and lead to the association of specific biofilms with 
health or disease.  It is possible that cats affected with FCGS have an intolerance 
to even small quantities of bacterial plaque on the tooth or tissue surface, and 
while some cats respond well to improved oral hygiene alone, others will respond 
poorly to all treatments.  Extraction of teeth is the standard treatment option for 
FCGS, of which 87% of cats show signs of improvement while 13% do not respond 
and may be considered refractory cases (Hennet, 1997; Girard and Hennet, 2005).  
Many drug-therapies, including anti-inflammatories, have been advocated for 
FCGS with limited efficacy, highlighting the urgency for novel treatment options.  
Previous research into human oral disease has led to the development of several 
multi-species biofilm models such as for gingivitis and periodontitis, which has 
allowed the study of specific bacterial interactions which mimic a disease-
associated environment (Millhouse et al., 2014; Park et al., 2014). However, as 
feline oral disease is less-well studied, there is not currently a comparative model 
to study bacterial roles in feline oral disease.  In this chapter, a multi-species 
biofilm containing bacteria associated with disease during FCGS was developed to 
evaluate the ability of novel actives to disrupt biofilms. 
 
All bacterial species considered as putative pathogens of FCGS (P. multocida 
subsp. multocida, P. multocida subsp. septica, T. forsythia, and P. 
circumdentaria) (Dolieslager et al., 2011) were shown to display sialidase activity 
in this study.  This was consistent with previous studies which have shown P. 
multocida species to produce medium-strong sialidase activity, and shown T. 
forsythia to display sialidase activity allowing it to utilise sialoglycoproteins for 
biofilm growth (Müller and Mannheim, 1995; Roy et al., 2011).  P. circumdentaria 
has also shown to display levels of sialidase activity (Assis et al., 2013).  Moreover, 
previous studies have shown a novel plant-derived compound, berberine, to cause 
inhibitory effects on both viral and bacterial sialidases making this a compound of 
interest in this study (Wu et al., 2011; Kim et al., 2014).  When treated with 
berberine, sialidase activity of all bacteria was shown to significantly decrease 
when increasing concentrations of up to 20 mM were used, concurrent with 
previous research.  The compound DANA has previously shown to be an effective 
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viral sialidase inhibitor, with less research reporting its potential as a bacterial 
sialidase inhibitor.  In this study, an 80% decrease in the fluorescence of P. 
multocida subsp. septica was shown following treatment with DANA, as well as 
concentration-dependent reductions in fluorescence for P. multocida subsp. 
multocida and T. forsythia.  This suggests that DANA may be a suitable sialidase 
inhibitor for some FCGS-associated bacteria.   
 
A comparative assessment of anti-microbial compounds: berberine, CHD-FA, 
xylitol and ubiquinol against a 10-species biofilm containing FCGS-associated 
bacteria was performed.  Berberine was found to reduce the biomass of the 
biofilm in a concentration-dependent manner up to 200 µg/mL, correlating to a 
previous study which found berberine to have anti-biofilm potential against 
Pseudomonas and Salmonella species (Aswathanarayan and Vittal, 2018).  The 
reduction in biofilm biomass with berberine treatment may support its potential 
to inhibit bacterial sialidase activity, as shown in the current study.  Furthermore, 
one study by Sherry et al. (2013) observed a killing and disruptive effect of CHD-
FA on multi-species periodontal biofilms when treated with 0.5% (v/v) for 24 h.  
In this study, results corroborated with previous research, with the greatest 
reduction in biofilm cell viability shown when biofilms were treated with CHD-FA 
at 0.8% (v/v); an antimicrobial effect comparative to that caused by the positive 
CHX control.  Biofilm biomass was also decreased by CHD-FA in a concentration-
dependent manner.  Xylitol did not significantly affect cell viability or biomass 
when treated at each concentration.  A previous study has shown xylitol to inhibit 
the formation of an oral multi-species biofilm containing species such as 
Streptococcus and Porphyromonas (Badet et al., 2008).  However, the research by 
Badet et al. (2008) did not investigate the ability of xylitol to decrease the 
viability and biomass of a mature biofilm, as carried out in this study, which may 
explain the differences observed.  Similarly, treatment with ubiquinol did not 
cause any significant changes in the viability or biomass of the biofilm at any 
concentration.  Thus far, there is limited research on the effect of ubiquinol on 
bacterial biofilms in vitro, however an in vivo study by Sugawara (2011) found 
that patients with periodontal disease treated with ubiquinol for 2 months showed 
a significant reduction in bacterial plaque adhesion.  Biofilms treated with xylitol 
and ubiquinol, however, did show to have a notable increase in the recovery of 
anaerobic bacteria (FAA) compared to aerobic bacteria (CBA).  This may suggest 
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that aerobic bacteria were more susceptible to these treatments or may have 
been outcompeted by anaerobes for nutrients. Quantifying the changes in the 
proportion of each bacterial species within the biofilm following treatment would 
be highly advantageous with further use of this model to allow susceptible and 
resistant species to be identified.   
  
In summary, the FCGS multi-species model presented in this study has displayed 
ability to test anti-microbial compounds and, with further quantification, could 
be valuable in more widespread testing of potential active compounds. 
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4 General Discussion 
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4.1 Introduction 
  
FCGS is a complex disease, with excessive oral inflammation believed to be driven 
by a multitude of interactions between various external stimuli and host immune 
cells in the oral cavity.  The series of observations herein addresses how the 
presence of specific bacteria within the oral cavity may influence the host 
response.  This was demonstrated by the use of an in vitro model system to 
measure host cell inflammatory changes upon challenge with bacteria associated 
with FCGS, and this system successfully displayed clear differences in the host 
response to each bacterial species.  Furthermore, a biofilm model that represents 
FCGS-associated plaque was developed to investigate novel treatment options for 
this.  This model system has demonstrated the efficacy of biologically active 
molecules on FCGS-associated biofilms, and the utility of this model could allow 
for future investigations on bacterial-host interactions including use in a co-
culture model with appropriate host cells. 
  
4.2 Conclusions and future work 
 
The major aims of this study were to investigate the inflammatory effects of 
bacteria associated with FCGS on host cells and examine the ability of novel 
compounds to disrupt FCGS-associated bacteria within a multi-species biofilm 
model.  Through the development of an in vitro assay, the TLR activation and pro-
inflammatory IL-8 gene and protein expression of host cells could be measured 
following exposure to varying multiplicities of infection of FCGS bacteria.  IL-8 
was appropriate in this study as it is used as a biomarker for inflammation in many 
clinical conditions (Shahzad et al., 2010).  With suspected pathogens of FCGS 
showing to elicit the activation of TLRs in this study, it was suggested that these 
bacteria are capable of triggering the metabolic pathologies of the immune 
response.  Furthermore, it was shown that human THP1-XBlueTM cells had the 
greatest increase in both IL-8 gene and protein expression when stimulated by T. 
forsythia and P. gingivalis at an MOI of 200, which could be expected as these 
bacteria are routinely identified in subgingival plaque in humans with chronic oral 
disease and contribute to disease pathogenesis (Socransky et al., 1998).  The 
release of IL-8 in cell culture supernatants further suggests that these bacteria 
may be involved in the initiation of the NF-κB pathway leading to a cascade of 
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chemokines and cytokines, and subsequent inflammation (Bennett et al., 2012).  
However, further research is required to prove whether the initiation of an IL-8 
response in cells is the direct result of TLR stimulation.  Using human cells 
provided an effective comparator to the feline SCCF1 cell line as bacterial 
involvement in human oral disease is more well understood.  SCCF1 cells were 
used in this study to make the results more relevant to FCGS.   
 
The feline SCCF1 cells showed a significantly increased IL-8 mRNA and protein 
expression following exposure to the bacteria suspected to be involved in FCGS 
(T. forsythia, P. circumdentaria and P. multocida species), which supports the 
idea that these bacteria have some involvement in the induction of a chronic 
inflammatory response during FCGS.  However, SCCF1 cells also presented a 
similar pattern of gene expression and protein release in the presence of B. 
zoohelcum.  As B. zoohelcum is regarded as a commensal organism in the feline 
oral cavity, an elevation of IL-8 levels was not expected and so the results using 
this cell line do not support B. zoohelcum as a commensal.  Previous research has 
also suggested that B. zoohelcum could cause harm to cats when it was isolated 
in pure culture from lung tissues of cats with respiratory disease, indicating at 
least partial involvement in disease (Decostere et al., 2002).  However, it must be 
considered that commensals work in unison with other species to form the healthy 
oral microbiota in vivo, and this behaviour may not be evident when studying this 
bacterium in isolation.  Therefore, B. zoohelcum may play a greater role in the 
progression of FCGS than initially expected but future work would be necessary to 
determine the inflammatory potential of B. zoohelcum and investigate its role in 
oral disease in the presence of FCGS recognised pathogens.  This in vitro assay 
could be used in further investigations to measure and compare the influence of 
specific FCGS-associated bacteria on other signature pro-inflammatory cytokines 
including tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ) which 
have shown to have elevated mRNA expression in tissue biopsies of cats with FCGS 
compared to a healthy group (Dolieslager et al., 2013).  It would also be of interest 
to determine the impact on the host immune response if host cells were 
stimulated with these bacteria in combination, or within a biofilm.  Furthermore, 
additional experiments using the in vitro model system to look at innate immune 
responses from epithelial cells isolated from feline gingival tissue would be useful 
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to investigate the aetiology and pathogenesis of FCGS, as these cells would most 
closely model the response of host oral cells in vivo. 
 
Many treatments have been advocated for FCGS, with most aiming to reduce the 
abnormal inflammatory response affecting the oral cavity.  While the pathological 
mechanism of FCGS remains unclear, it is thought that increased plaque 
accumulation within the oral cavity may be a key predisposing factor of FCGS.  
Elective tooth extraction, which removes plaque retentive surfaces in the mouth, 
has become the accepted standard method of managing FCGS in cats and has 
proven efficacy with up to 80% of cats showing substantial or complete 
improvement (Hennet, 1997; Girard and Hennet, 2005).  Another recommended 
method of management for FCGS is to implement the improvement of feline oral 
hygiene throughout all stages of treatment.  This involves daily teeth brushing 
with the use of chlorhexidine toothpaste and oral rinses with the aim to reduce 
the level of plaque build-up and help minimise opportunistic infection of inflamed 
oral tissue.  However, the majority of cats will not fully respond to this cleaning 
or extraction alone and extended or continuous medical treatments are required 
(Jennings et al., 2015).  It is apparent that the elimination of bacterial plaques is 
of importance in the management of FCGS and investigating new treatment 
options to target these external stimuli could be vital to reduce refractory cases 
of FCGS.  
 
It has been proposed that sialidase inhibitors could be of pharmacological 
relevance in the treatment of FCGS. Previous studies have implied the importance 
of sialidase enzymes of some pathogenic bacteria for biofilm formation and 
colonisation of mucosal surfaces (Oggioni et al., 2006; Parker et al., 2009).  
Sialidases likely contribute to virulence through cleavage of sialic acids in mucosal 
tissues, which bacteria utilise to obtain food and energy during the formation of 
a dental biofilm.  Several pathogens have shown to use sialidases in virulence such 
as Streptococcus pneumoniae and T. forsythia (Corfield, 1992).  T. forsythia has 
previously shown to use the sialidase enzyme NanH in initial biofilm formation 
(Roy et al., 2011). The use of sialidase inhibitors for the treatment of FCGS has 
been suggested due to the ability of these inhibitors to target a common binding 
site (α-2,6-linked sialic acid) in putative pathogenic bacteria, which could prevent 
plaque biofilm formation and invasion of bacteria in disease.  In this study, it was 
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shown that all putative pathogens of FCGS (T. forsythia, P. circumdentaria, P. 
multocida supsp. multocida, and P. multocida subsp. septica) displayed a medium 
to high level of sialidase activity, suggesting that the sialidase enzyme could 
contribute to the virulence of these bacteria during disease.  Furthermore, with 
bacteria showing a 70-90% decrease in sialidase activity following berberine 
treatment and a 60-80% decrease in sialidase activity following DANA treatment, 
this work provided evidence that these compounds could be considered as 
alternative drug therapies for the reduction of dental plaque biofilms in FCGS.  It 
would be necessary to investigate the toxicity of the inhibitors at effective 
concentrations as well as consider associated costs. 
 
A variety of research has shown the development of modelled oral biofilms that 
recapitulate the microbial environment in oral disease in attempt to understand 
bacterial interactions during disease and allow development of new 
chemotherapeutic agents (Periasamy and Kolenbrander, 2009; Sherry et al., 
2016).  Given that most bacteria exist as multi-species consortia in the oral cavity, 
creating a multi-species model for testing is advantageous as it allows a controlled 
and reproducible environment with a more realistic measure of bacterial 
susceptibility in vivo than studies of an individual component species (Tan et al., 
2017).  Moreover, the importance of biofilm models for the study of antimicrobials 
has been highlighted when the minimum inhibitory concentration (MIC) of oral 
bacterial species such as F. nucleatum and P. gingivalis, following treatment with 
CHX, was found to be 10,000 times lower for planktonic cells than single species 
biofilms (Park et al., 2014).  In this study, a complex biofilm model comprising 
bacteria associated to a diseased microbial environment in the feline oral cavity 
during FCGS was created as a platform for testing the efficacy of novel 
compounds.   
 
The feline oral cavity has a diverse and unique microbiota, comprising over 400 
bacterial species (Adler et al., 2016).  A defined group of bacteria were chosen to 
use in the FCGS biofilm model with properties that increased the chances of a 
mature biofilm to successfully develop.  This included early colonisers 
(Streptococcus species) which initially attach to the tooth surface in early biofilm 
growth, and F. nucleatum which is a known bridging organism that other organisms 
will bind to promoting maturation of the dental plaque biofilm (Settem et al., 
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2012).  F. nucleatum has also shown to facilitate the survival of obligate anaerobes 
within a biofilm in aerated environments; a property that would be advantageous 
for this biofilm model due to the addition of strictly anaerobic FCGS-associated 
pathogens (T. forsythia and P. circumdentaria).  The bacteria were added in a 
sequential manner to ThermanoxTM coverslips in a biologically relevant media to 
allow the formation of the biofilm model to mimic plaque development in vivo.  
In this study, biological agents of interest were applied directly to the mature 
multi-species biofilm and the efficacy determined by measuring biofilm viability 
and biomass.   
 
Our group has previously shown a natural compound (CHD-FA) to be highly 
effective against a multi-species periodontal biofilm at a concentration of 0.5% 
(Sherry et al., 2013).  In this study, CHD-FA was the most effective compound 
tested against the FCGS multispecies biofilm, where 0.8% CHD-FA was able to 
disrupt cell viability to the same level as CHX, which is currently used as a 
treatment for FCGS.  CHD-FA could potentially be used as an alternative natural 
agent to CHX to eliminate plaque biofilms in FCGS as it has shown no sign of 
toxicity in rats and humans and has shown to have anti-inflammatory properties 
(Gandy et al., 2012; Gandy et al., 2011).  Furthermore, in this study, significant 
disruption of the multispecies biofilm biomass was observed when treated with 
0.5% CHD-FA which corroborates with research by Sherry et al. (2013).  That study 
found, through SEM imaging, disaggregation of bacterial biofilms following CHD-
FA treatment, indicating possible action against the bacterial cell membrane.  
Collectively, these properties make CHD-FA a desirable option for the 
development of a topical agent such as a toothpaste or mouthwash to control 
microbial dysbiosis in FCGS.  However, further studies to assess the effect of CHD-
FA on the host and determine its efficacy in vivo would be required. 
 
Previous work has found berberine, a naturally occurring chemical compound, to 
have anti-biofilm properties (Aswathanarayan and Vittal, 2018).  In this study, it 
was also shown that the biomass of the multispecies biofilm was significantly 
disrupted following treatment with berberine.  Compounds with the ability to 
disrupt biofilm structure are valuable in oral disease to increase the vulnerability 
of plaque bacteria to antimicrobial agents.  Berberine has been used as a 
therapeutic agent in clinical applications due to its inherent low cytotoxicity 
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(Chung et al., 1999). Although the mode of action of berberine is not fully 
understood, this investigation indicated the potential for berberine to block 
bacterial sialidase activity as a mechanism to disrupt bacterial attachment and 
biofilm formation.  Further investigations to understand the mode of action, and 
assessment of the cytotoxicity of berberine on feline host cell lines, would be of 
importance to evaluate the safety of this compound for clinical use.    
 
Despite previous work showing the five-carbon polyol, xylitol, to have anti-biofilm 
properties and reduce plaque accumulation, it had no significant effect on the 
multispecies biofilm at the concentrations tested in this study (Badet et al., 2008; 
Milgrom et al., 2012).  Moreover, treatment with ubiquinol did not have any effect 
on the biofilm viability or biomass.  It is possible that the mature multispecies 
biofilm was too robust for the concentrations of these compounds tested.  It could 
be of value to perform additional experiments to determine the MIC of these 
compounds on planktonic cells or single species biofilms of the bacteria of 
interest, which are more susceptible than the multi-species biofilm, to identify if 
these compounds have any antibacterial potential on FCGS-associated bacteria.  
It would also benefit to measure the effect of compounds on the biofilm at various 
timepoints, to determine if there is a time-dependent impact.  One limitation of 
this study was the inability to quantify the live/dead bacteria in the multispecies 
biofilm before and after treatment using molecular techniques due to time 
restrictions, which is of importance to provide a reproducible model.  With further 
work to validate this FCGS model, it could be used in future applications with local 
tissue and immune cells to study how biofilm composition modulates pro-
inflammatory cytokine and chemokine gene expression, as well as protein release.  
 
To conclude, the work in this thesis provides valuable information regarding the 
role of bacterial composition in the modulation of host-pathogen interactions and 
evaluated the antimicrobial activity of novel compounds for potential use in FCGS 
treatment. Together, these allow for a greater understanding of the 
aetiopathogenesis of FCGS and provide a basis for the development of alternative 
therapies to tackle this complex feline disease. 
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